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Abstract: Nonobstructive azoospermia (NOA) represents the most severe expression of male infertility,
involving around 1% of the male population and 10% of infertile men. This condition is characterised
by the inability of the testis to produce sperm cells, and it is considered to have an important genetic
component. During the last two decades, different genetic anomalies, including microdeletions of the
Y chromosome, karyotype defects, and missense mutations in genes involved in the reproductive
function, have been described as the primary cause of NOA in many infertile men. However, these
alterations only explain around 25% of azoospermic cases, with the remaining patients showing an
idiopathic origin. Recent studies clearly suggest that the so-called idiopathic NOA has a complex
aetiology with a polygenic inheritance, which may alter the spermatogenic process. Although we are
far from a complete understanding of the molecular mechanisms underlying NOA, the use of the
new technologies for genetic analysis has enabled a considerable increase in knowledge during the
last years. In this review, we will provide a comprehensive and updated overview of the genetic basis
of NOA, with a special focus on the possible application of the recent insights in clinical practice.
Keywords: male infertility; azoospermia; genetic component; mutations; SNPs
1. Introduction
Infertility is becoming a growing global public health issue according to the World Health
Organization (WHO, Geneva, Switzerland), which is warning about the relevant impact that this
condition has on society and the economy. Despite the difficulty in estimating the prevalence of male
and female contributions to infertility, it has been reported that about 50 million couples worldwide may
be affected, with male infertility contributing to half of those cases approximately [1,2]. Nonobstructive
azoospermia (NOA) is considered the clinically most severe expression of male infertility, affecting
around 1% of the male population and 10% of infertile men [3–7]. This condition is defined by a
complete lack of sperm cells in the ejaculate without any reproductive tract obstruction, likely related
to a failure in the spermatogenic process [8]. However, such a phenotype has extremely diverse causes
(influencing different processes like gonad differentiation, the hypothalamic–pituitary axis function,
and spermatogenesis), making this a highly heterogeneous disease [9]. Single genetic anomalies
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(including chromosome aberrations and point mutations) can explain around 25% of NOA patients,
with the remaining patients being classified as idiopathic [10]. In this regard, cumulating knowledge
clearly suggests that idiopathic NOA has a multifactorial aetiology, in which both environmental and
genetic factors may contribute to disease development. In these cases, the genetic predisposition is
likely conferred by common variations of the human genome, mostly single-nucleotide polymorphisms
(SNPs) and copy number variants (CNVs), which complicate the elucidation of the underlying
pathological mechanisms [9]. Identifying the genetic risk factors of NOA would definitively help
urologists to improve both care and counselling of affected men.
This review aims to summarise the current knowledge on the genetic background of NOA, with
emphasis on the potential impact that the recent insights could have in the management of affected
individuals who hope to father a biological child.
2. The Spermatogenic Process
The testis represents a crucial organ for male individuals, since it is responsible for androgen
production and generation of sperm cells that will carry the genetic inheritance to the offspring. This
organ develops from a gonadal primordium that has the potential to differentiate either as testis or
ovary. As a consequence, the molecular network underlying gonad development and function is
extremely complex, and subtle alterations may produce very relevant clinical phenotypes [11].
After puberty, hundreds of millions of male gametes are generated daily within the wall of the
seminiferous tubules in a process known as spermatogenesis [12]. This process implies a series of
events in a stepwise fashion, including several division rounds of diploid spermatogonial stem cells
(SSCs), meiosis of spermatocytes, and morphological differentiation of spermatids (Figure 1). Once
all these steps are completed, mature spermatozoa are released into the lumen of the tubule so they
can be stored in the epididymis until ejaculation. In humans, the whole process is estimated to take
around three months, and it requires a delicate physical and molecular interaction between germ cells
and Sertoli cells, which are the somatic supporting cells of the tubule. Other somatic cells outside the
tubule, such as Leydig and peritubular-myoid cells, are also important for this cross-talk [13,14].
Figure 1. Schematic illustration of spermatogenesis. Genes with reported mutations associated with
nonobstructive azoospermia are shown in the cells in which they are expressed. The font size correlates
with the strength of the evidence.
Different populations of spermatogonia have been described, all of them residing in the innermost
part of the tubule wall. Molecular markers common to all SSCs (e.g., FOXO1, CDH1, ZBTB16, SALL4,
and LIN28) as well as SSC type-specific markers (e.g., ID4, PAX7, BMI1, GFRa1, and NANOS2) have
been reported [15]. Once the differentiation program has been initiated, a self-renewing SSC divides
asymmetrically to maintain the undifferentiated pool and to generate a new spermatogenic lineage
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(A-aligned spermatogonia). At this step, a genetic commitment to complete the spermatogenic process
has been initiated, leading to differentiation to A1 spermatogonia, which are characterised by the
expression of the cKIT receptor. Subsequently, A1 spermatogonia undergo several mitotic divisions
generating A2, A3, A4, intermediate and B spermatogonia, and primary spermatocytes that will initiate
meiosis to produce haploid secondary spermatocytes. Finally, biologically functional male gametes
will be produced by morphological maturation of secondary spermatocytes, which will differentiate
into spermatids and spermatozoa in a process known as spermiogenesis [16].
Because of the high relevance and complexity of the spermatogenesis process, a large number of
molecules are involved in its regulatory mechanisms, such as the GnRH/FSHLH, GDNF/RET/GFRA1,
FGF2/MAP2K1, CXCL12/CXCR4, retinoic acid, androgen and oestrogen signalling pathways [16–18].
Indeed, it has been estimated that more than 2000 genes may be involved in the maintenance of the
germ cell population and satisfactory accomplishment of meiosis [19]. Besides, epigenetics and DNA
integrity have been also shown to play relevant roles in this process [20,21]. Therefore, alterations of
such mechanisms may result in the development of infertility issues [10].
3. Monogenic Causes of Nonobstructive Azoospermia
Around 10% of male infertility diagnoses are due to azoospermia [22]. Known causes of
azoospermia include endocrine and chronic diseases that affect the hypothalamic–pituitary–gonadal
axis (e.g., hypogonadism or diabetes), but also pathologic conditions that disrupt the transport of
sperm through the vas deferens (e.g., maldescended testes, varicocele, malignancy, or urogenital
infections) [23]. However, in one-third of azoospermia patients there is a discernible genetic anomaly
responsible for spermatogenic failure [6]. In this regard, genetic diagnostic testing for azoospermia is
usually based on the detection of karyotype aberrations, Y chromosome microdeletions, and cystic
fibrosis transmembrane conductance regulator (CFTR) mutations [24].
3.1. Karyotype Abnormalities
It is widely known that the presence of cytogenetic defects may interfere with the spermatogenic
process. In this regard, the aneuploidy rate in NOA patients is ten times higher than that observed in
men with obstructive azoospermia [25]. Indeed, sex chromosome aneuploidies represent the most
common cause of NOA, especially Klinefelter syndrome (47, XXY) [26–28]. This syndrome affects
approximately 0.15% of men, which show testicular atrophy and dysfunction as a consequence of
hyalinization of the seminiferous tubules at mid-puberty, with loss of germ cells and hyperplasia of
Leydig cells [29]. However, although more than 95% of Klinefelter patients have an NOA diagnosis,
focal spermatogenesis has been observed in cases of mosaicism 47, XXY/46, XY in the germ line,
allowing these individuals to father a child by testicular sperm extraction (TESE) techniques [30].
Other structural chromosome mutations have been also associated with NOA, including sex
and autosomal chromosome rearrangements, and translocations between X and Y chromosomes or
between sex chromosomes and autosomes, which may involve crucial genes for spermatogenesis [28].
3.2. Y Chromosome Microdeletions
The key role in spermatogenesis of a genomic region within the long arm of the Y chromosome
(Yq) has been known for more than four decades [31]. Different studies reported that several terminal
and interstitial microdeletions of Yq were associated with NOA, identifying three distinct intervals
essential for male fertility that were called azoospermia factor (AZF) a, b, and c (located in proximal,
middle, and distal Yq11 subregions, respectively) [32,33]. Subsequently, with the use of more advanced
sequencing methods, different breakpoint hotspots involving five major palindromes (labelled P1
through P5) were identified [34]. However, in clinical practice, the AZF nomenclature is still used
to define the different deletion patterns, i.e., AZFa, AZFb (P5/proximal P1), AZFbc (P5/distal P1 or
P4/distal P1), and AZFc (b2/b4) [35].
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The Yq microdeletions are a consequence of intrachromosomal non-allelic homologous
recombination events (due to the highly repetitive structure of the Y chromosome) [36–39], and
overall they are present in 5%–10% of azoospermic patients [40]. The deleterious effect on male fertility
is caused by the loss of several key regulatory genes of spermatogenesis [35]. Some of them are
described below.
3.2.1. USP9Y
USP9Y (ubiquitin-specific protease 9, Y chromosome, MIM*400005), also known as DFFRY
or SPGFY2, represents one of the major AZFa genes. It encodes a member of the peptidase C19
family that confers stability and protection to ubiquitin-conjugated proteins involved in germ cell
survival, through their deubiquitination [41,42]. Its expression is restricted to spermatids, and point
mutations in this gene can lead to different clinical phenotypes of male infertility related to reduced
mobility and concentration of sperm cells, including spermatid maturation arrest, oligospermia, or
asthenozoospermia [43–47]. Similarly, complete loss of the gene has been associated with NOA [48,49].
3.2.2. DDX3Y
The protein encoded by DDX3Y (DEAD/H box 3, Y-linked, MIM*400010), another AZFa gene
formerly known as DBY, belongs to a family of ATP-dependent helicases involved in the regulation of
the cell cycle through intramolecular interactions during RNA transcription, translation, and intron
splicing [50]. A testis-specific expression of some DDX3Y isoforms has been reported, particularly in
the male germ line [51,52]. Interestingly, there is a homologue DDX3Y in the X chromosome (DDX3X)
that shares around 95% of the DNA sequence and seems to have similar molecular functions. However,
DDX3X is mostly expressed during spermatid maturation and DDX3Y in early meiosis [53,54].
Although there is no direct evidence yet, it is likely that depletion of DDX3Y results in Sertoli cell-only
syndrome (SCO) [35].
3.2.3. EIF1AY
One of the genes located within the AZFb region is EIF1AY (eukaryotic translation initiation factor
1a, Y-linked, MIM*400014) [55]. Its encoded protein plays an important role in start codon recognition
by the translation initiation machinery during spermatogenesis [56]. It has been suggested that the
absence of EIF1AY expression may contribute to NOA development [57].
3.2.4. RPS4Y2
RPS4 refers to a highly conserved protein family involved in mRNA binding to the ribosome [58].
In nonhuman primates, two RPS4 genes have been described, named RPS4X and RPS4Y (located
in chromosome X and Y, respectively). Interestingly, the human RPS4Y has two functional Y-linked
paralogs, named RPS4Y1 (ribosomal protein s4, Y-linked, 1, MIM*470000) and RPS4Y2 (ribosomal
protein s4, Y-linked, 2, MIM*400030), which makes this a unique feature compared to other ribosomal
proteins [59,60]. In contrast with its X-linked homologue, RPS4Y2 has a testis-specific expression
pattern, being proposed as a key player in the post-transcriptional regulation during germ cell
development [59,61]. The fact that RPS4Y2 maps within the AZFb region makes this gene a good
candidate to explain the development of male infertility traits when this genomic region is depleted [35].
3.2.5. KDM5D
Another relevant AZFb gene is KDM5D (lysine-specific demethylase 5d, MIM*426000), also known
as JARID1D. It encodes a conserved protein of the family of histone demethylases, which have crucial
roles in the epigenetic regulation of gene expression. KDM5 proteins catalyse the removal of methyl
groups from histone H3 lysine 4 methylation marks (H3K4me) in the genome, acting as transcriptional
repressors [62,63]. It has been observed that KDM5D-mediated H3K4 demethylation is required for
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sexually dimorphic gene expression, and defects in the regulatory mechanism of this enzyme have
been associated with different tumorigenic processes [64,65]. Regarding spermatogenesis, it seems that
KDM5D is directly involved in chromatin remodelling and condensation during meiosis, acting in a
cooperative manner with the MSH5 DNA repair factor [66,67].
3.2.6. DAZ
Because of the evolutionary history of the sex chromosomes, the Y chromosome contains
several ampliconic regions (male specific-sequences of the Y chromosome enriched with large
segmental duplications that involve frequently complex structural arrangements), most of them
located in the AZFc region, which have been evolved from X chromosome or even autosome
counterparts [68]. The amplicons are arranged as direct repeats, inverted repeats, or palindromes,
giving rise to multiple copies of the so-called “ampliconic genes”, which are prone to undergo
processes of intra-chromosomal recombination events, in a process known as “gene conversion”.
Interestingly, these multicopy genes show variations in their sequence, structure, and copy number
amongst individuals [69]. As a consequence of this large sequence identity, deletions involving
the AZFc region represent the most common Yq microdeletions (more than 80%) and have been
directly involved with NOA development [39,70]. One of these multicopy gene families is DAZ
(deleted in azoospermia, MIM*400003), which evolved from the autosomal gene DAZL (deleted in
azoospermia-like, MIM*601486) [71]. DAZ has four copies distributed into two different clusters
(DAZ1/2 and DAZ3/4), and their expression is restricted to the testis [72]. It encodes an RNA-binding
protein involved in RNA translation during sexual differentiation of XY germ cells, acting as antagonist
of NANOS, another essential protein required for meiosis initiation [73]. Conditional inactivation of
Dazl in the gonads of mouse models leads to complete absence of gamete production, highlighting the
essential role of these proteins in gametogenesis [74].
Other multicopy gene families (involving ampliconic regions of the Y chromosome) potentially
related to spermatogenesis and, therefore, are a candidate for NOA development include TSPY
(testis-specific protein, Y-linked, MIM*480100, with 35 copies), VCY (variably charged, Y chromosome,
MIM*400012, with 2 copies), XKRY (XK-related protein on Y chromosome, MIM*400015, with 2
copies), CDY (chromodomain protein, Y chromosome, MIM*400016, with 4 copies), HSFY1 (heat-shock
transcription factor, Y-linked, MIM*400029, with 2 copies), RBMY (RNA-binding motif protein, Y
chromosome, MIM*400006, with 6 copies), PRY (PTPBL-related gene on Y, MIM*400019, with 2 copies),
and BPY2 (basic protein, Y chromosome, 2, MIM*400013, with 3 copies) [35].
3.3. Autosomal Monogenic Factors
The widespread application of novel technologies for genetic investigation of human disorders,
such as next-generation sequencing (NGS), has allowed the identification of a large number of mutations
in putative male infertility genes [75]. However, because of the lack of validation studies in most cases
(and the considerably lower incidence of known monogenic alterations in male infertility compared to
chromosomal abnormalities), the routine for genetic diagnostic testing has remained unaltered during
the last two decades. Current genetic tests are based on karyotyping, analysis of the AZF region, and
the screening of gene mutations associated with congenital hypogonadotropic hypogonadism (CHH, a
very rare condition characterised by gonadotropin deficiency and low levels of sex steroid hormones)
and obstructive azoospermia, being effective only in around 20% of azoospermic men [76]. Some of
the described NOA genes with a potential value as diagnostic markers for NOA are summarised in
this section.
3.3.1. AR
AR (androgen receptor, MIM*313700), also known as DHTR (dihydrotestosterone receptor),
represents the only gene that is currently considered for genetic testing and counselling in the diagnosis
of NOA [10]. AR is an X-linked gene that encodes a transcription factor of the steroid-hormone
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activated receptor family, which regulates the expression of androgen-responsive genes upon binding
to the hormone ligand [77]. Androgens are essential steroid hormones for male sex development
as well as the maintenance of male reproductive organs and spermatogenesis, through binding to
AR [78,79].
The total number of reported AR mutations exceeds 1000 (many of them representing
non-synonymous mutations altering the DNA binding site), with a wide spectrum of associated
phenotypes ranging from the complete androgen insensitivity syndrome (phenotypic female 46, XY
individuals) to a mild form of androgen insensitivity in azoospermic males with apparently normal
testes [80].
Mutant mice for this gene exhibit pathological phenotypes similar to those observed in humans [81].
Interestingly, conditional knock-out mice in which Ar was selectively depleted in Sertoli cells showed
meiotic arrest in spermatocytes, thus highlighting the relevant role that androgens may have for the
spermatogenic function [82].
AR is a highly polymorphic gene that contains two variable number tandem repeats (VNTRs),
(CAG)n and (CGN)n (encoding for glycine and glutamine, respectively) in the N-terminal domain
(located in exon1) [83]. The length of the CAG repeats has been associated with different human
disorders, including impaired sperm production and male infertility [84]. In this regard, the possible
implication of the CAG repeat in the development of NOA has been extensively investigated [85].
Although the results have been controversial in some cases, it has been proposed that long CAG repeats
may increase the predisposition of male infertility due to impaired androgen function [86,87].
3.3.2. NR5A1
The protein encoded by NR5A1 (nuclear receptor subfamily 5, group A, member 1, MIM*184757),
also known as SF1 and AD4BP, belongs to the family of nuclear receptors, which has a central
role in many aspects of tissue development and function [88]. The expression of this gene was
initially located in the main steroidogenic tissues of the adult mouse (adrenal cortex, testis, and
ovary), related to the synthesis of steroids. Shortly after, it was discovered that it also played an
important role in the synthesis of gonadotropins as well as in sex differentiation and development
of both the gonad and the adrenal gland [89–94]. Indeed, the SF-1 protein is a transcription factor
that modulates the timing and expression levels of many target genes, including key players of the
hypothalamic–pituitary–steroidogenic axis [95].
Mutations of Nr5a1 in mouse models cause abnormal development of the hypothalamus and
pituitary gland, showing absence of both luteinizing and follicle-stimulating hormones [93]. Knock-out
mice are born at the expected age, but shortly after birth they die due to adrenocortical insufficiency.
These mice lack adrenal glands and gonads, and XY individuals develop Mullerian ducts resulting in
internal female genitals [94,96].
In humans, different clinical conditions have been associated with autosomal dominant mutations
of NR5A1, including primary adrenal insufficiency, primary ovarian insufficiency, and different
alterations of male sexual development, such as 46, XY sex reversal, anorchidism, hypospadias,
testicular dysgenesis, and spermatogenic failure [97].
Regarding NOA, in 2010 Bashamboo and colleagues [98] screened the coding sequence of NR5A1
in a population of mixed ancestry composed of 315 men with idiopathic spermatogenic failure and 729
healthy controls (359 normozoospermic men and 370 males with self-reported paternity of at least
two children). Interestingly, they identified heterozygous missense mutations in four azoospermic
individuals (3.9% of all azoospermic men analysed) and two patients with severe oligospermia (4.3%
of men with this phenotype). Noteworthy, the control population did not show any rare variation, and
the described mutations were not found in more than 2100 additional control samples.
Three years later, the Tuttelmann’s group conducted a similar study in a German cohort of 478
patients with diagnosis of spermatogenic failure (270 with NOA and 218 with severe oligospermia) and
237 men with normal semen parameters [99]. The authors identified three additional heterozygous
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missense mutations with predicted pathogenicity in protein function (one of them in an NOA
patient). Several synonymous mutations were also observed, although they were present in some
control individuals.
In 2015, two studies reported additional heterozygous NR5A1 non-synonymous mutations in
NOA patients. Ferlin and collaborators [100] observed seven novel NR5A1 missense mutations in
Italian subjects with severe spermatogenic impairment, three of them carried by NOA patients (one
with idiopathic NOA and two with unilateral cryptorchidism). Similarly, two Iranian NOA patients
were reported to harbour heterozygous NR5A1 missense mutations out of 90 azoospermic patients
analysed [101]. In either study, no mutations were detected in fertile individuals, with or without
history of cryptorchidism [100,101].
In contrast with the previously mentioned studies, in a recent screening on the Indian population,
no mutations within NR5A1 were detected in 414 NOA patients [102].
3.3.3. DMRT1
DMRT1 (doublesex- and MAB3-related transcription factor 1, MIM*602424) belongs to the DMRT
family, which encodes a group of highly conserved transcription factors involved in sex determination
and gonadal development of several metazoan phyla [103]. This gene family represented the first
described case of sex regulatory genes in both vertebrates and invertebrates [104,105]. DMRT1
expression is detected in pre-Sertoli cells of the undifferentiated gonads shortly after male sex
determination (at the sixth week of pregnancy). Its expression remains active until adulthood,
representing a Sertoli cell marker [106].
Subtelomeric deletions of the short arm of the human chromosome 9 (in which DMRT1 is
located) have been associated with 46, XY sex reversal and gonadal dysgenesis in XY individuals [107].
Interestingly, smaller deletions encompassing DMRT1 were identified in five infertile men with
azoospermia but no symptoms of gonadal dysgenesis.
Unexpectedly, the experimental removal ofDmrt1 from the mouse genome caused no abnormalities
in either sex determination or the embryonic gonadal development. However, the testes of those mice
during postnatal development underwent rapid deformation due to a failure in the differentiation of
Sertoli cells, which showed uncontrolled proliferation and, finally, apoptosis. The germ cells, in turn,
did not migrate to the periphery of the seminiferous tubules and died also shortly after birth [108].
In relation to NOA, in 2013 Lopes and colleagues [109] identified deletions of the DMRT1 exonic
sequence in five subjects diagnosed with idiopathic NOA (two Europeans and three Han Chinese) from
a total cohort of 1423 azoospermic patients (323 Europeans and 979 Chinese) and 2834 fertile controls
(1100 Europeans and 1734 Chinese), through the analysis of large-scale genotyping data. Interestingly,
one of these individuals showed SCO.
One year later, Tewes and colleagues [110] analysed the DMRT1 sequence in 131 individuals
diagnosed with NOA and 215 normozoospermic controls, reporting two cases of NOA (one of them
with SCO) that showed heterozygosity for a putative pathogenic transition mutation in the third
exon of the gene. The DMRT1 mutation observed in the SCO patient was detected in another NOA
individual from Brazil (from a total of 16 azoospermic patients analysed) in a recent study [111].
Finally, in 2015, the Lopes’ group identified three additional noncoding variants located in
regulatory regions of DMRT1, by analysing a Portuguese study cohort of 155 NOA and 376 controls
(75 normozoospermic and 301 with self-reported fatherhood) using a multiplex ligation probe assay
and Sanger sequencing [112]. One of them, located in the promoter region, showed clear evidence of a
key regulatory role in Dmrt1 repression. In addition, the frequency of some coding and noncoding
DMRT1 rare variants were also significantly higher in the NOA group compared with the control one.
3.3.4. TEX11
TEX11 (testis-expressed gene 11, MIM*300311) was discovered in 2001 through cDNA subtraction
of specific transcripts of mouse spermatogonia that were not present in somatic cells [113]. It
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encodes a highly conserved meiosis-specific protein involved in the assembly and maintenance of
the synaptonemal complex during chromosome recombination in prophase I. Indeed, mutant mice
for Tex11 exhibited achiasmate chromosomes as well as impaired double-strand break repair and
chromosomal crossover [114]. Notably, TEX11 is an X-linked gene, which indicates the important role
that this sex chromosome may have in spermatogenesis.
In 2015, Yatsenko and colleagues [115] reported a hemizygous deletion of three exons of TEX11
(encoding a fragment of the meiosis-specific domain SPO22) in two NOA patients. In a subsequent
step, the authors performed a comprehensive mutation screening that revealed additional TEX11
mutations, including non-synonymous changes of the coding sequence and splicing mutations, in 7
out of 289 analysed NOA individuals. Interestingly, five of these patients harbouring TEX11 mutations
had a meiotic arrest (representing 15% of all patients with meiotic arrest in the study population)
that resembled the abnormal phenotype observed in mutant mice [114]. No single mutation was
observed in any SCO patient or in 384 normozoospermic controls. In addition, the authors confirmed
the expression of TEX11 in late-pachytene spermatocytes and in spermatids, being completely absent
in Sertoli cells [115].
The high relevance of TEX11 in NOA was further confirmed in different independent sequencing
studies [116–119], as well as in gene expression studies that reported a downregulation of TEX11 in
testis samples from MA patients compared to controls [120].
3.3.5. TEX14 and TEX15
TEX14 (testis-expressed gene 14, MIM*605792) and TEX15 (testis-expressed gene 15, MIM*605795)
represent two additional spermatogonium-specific genes identified by Wang et al. [113]. However,
contrary to TEX11, these two genes have an autosome location (chromosomes 17q22 and 8p12,
respectively), implying a double dosage in males. TEX14 encodes a protein kinase that is expressed
almost exclusively in male spermatogonia, in which it seems to regulate their differentiation [121–123],
whereas TEX15 encodes a protein with a function similar to that of TEX11 (double-strand DNA break
repair and chromosomal synapsis) that has been detected in both testis and ovaries [124]. Knock-out
mice for these two genes show spermatogenic failure at different levels (disruption of spermatogenesis
before the completion of the first meiotic division in Tex14 null mice, and meiotic arrest in Tex15 null
mice) [121,124].
In humans, different mutations of both genes have been recently described in NOA patients. Two
NOA brothers contained a 10 bp deletion within TEX14 that led to a truncated protein. Consistent
with the observations in animal models, the germ line population of both brothers consisted mostly of
undifferentiated spermatogonia [125]. In addition, Fakhro and collaborators [123] used whole-exon
sequencing in eight consanguineous families and described a deleterious recessive mutation within
TEX14 that segregated with disease. Regarding TEX15, three studies reported mutations associated
with NOA. Okutman and colleagues [126] identified a heterozygous nonsense mutation in three
Turkish brothers diagnosed with NOA and showing meiotic arrest, resulting in the generation of a
premature stop codon. Colombo and colleagues [127] performed exome sequencing in two infertile
siblings affected by NOA, identifying another nonsense mutation and a single nucleotide deletion that
led to premature stop codons in the TEX15 locus. Finally, the recent sequencing study of 16 Brazilian
patients affected by NOA by Araujo et al. [111] also reported novel rare variants in both TEX14 and
TEX15.
3.3.6. NPAS2
NPAS2 (neuronal PAS domain protein 2, MIM*603347) encodes a transcription factor of the basic
helix-loop-helix-PAS (bHLH-PAS) family that is mostly expressed in the central nervous system, in
which it seems to regulate the circadian rhythms of the forebrain by interacting with the circadian
locomotor output cycles kaput (CLOCK) proteins [128,129]. In 2015, Ramasamy and colleagues [130]
analysed a consanguineous Turkish family, which included three infertile brothers affected by NOA,
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and identified a missense mutation located in exon 14 of NPAS2. Notably, a family segregation
was observed, as all three siblings were homozygous for the mutation, whereas the mother and a
fourth, fertile brother were heterozygous. Besides, the NPAS2 mutation was not detected in a control
population of 50 fertile men. The authors proposed that the pathogenic effect of this mutation could
be related to a disruption in steroidogenesis, by affecting the interaction of NPAS2 with circadian
molecules like CLOCK.
3.3.7. Other Putative Nonobstructive Azoospermia Genes
Additional genes involved in spermatogenesis have been also proposed as single molecular
causes of NOA, but, in most cases, further functional and/or validation studies are required to confirm
the original findings. Some examples include SOHLH1 (spermatogenesis- and oogenesis-specific
basic helix-loop-helix protein 1, MIM*610224) [117,131], USP26 (ubiquitin-specific protease 26,
MIM*300309) [132,133], SYCP3 (synaptonemal complex protein 3, MIM*604759) [134], MEIOB
(meiosis-specific protein with OD domains, MIM*617670), DNAH6 (dynein, axonemal, heavy chain 6,
MIM*603336) [125], ZMYND15 (zinc finger MYND-containing protein 15, MIM*614312), TAF4B (TATA
box-binding protein-associated factor, MIM*601689) [135], SYCE1 (synaptonemal complex central
element protein 1, MIM*611486) [136], MCM8 (minichromosome maintenance complex component 8,
MIM*608187) [137],HSF2 (heat-shock transcription factor 2, MIM*140581) [138], SPINK2 (serine protease
inhibitor, KAZAL-type, 2) [139], and TDRD9 (TUDOR domain-containing protein 9, MIM*617963) [140],
amongst others [75] (Figure 1).
4. Common Variation Associated with Susceptibility to Nonobstructive Azoospermia
Despite the great progress made during the golden era of NGS in the elucidation of the genetic
causes of azoospermia, there remains a considerably large proportion of missing heritability that still
needs to be accounted for. Indeed, in a large proportion of patients with spermatogenic disturbances,
the aetiology remains unknown [141]. Many studies have been performed to shed light into the
so-called idiopathic NOA, but, in most cases, they have been strongly limited by low sample sizes and
heterogeneous inclusion criteria of the study groups [85,142] (Table 1).
4.1. Candidate Gene Approach
During the last three decades, big efforts have been made to identify candidate gene polymorphisms
associated with a complex form of idiopathic NOA. SNPs have been the most analysed variations,
with some studies on VNTRs and CNVs. Selected genes include those involved in hormone
production, regulation of the cell cycle, and spermatogenesis [85,142]. Although some significant
genetic associations with spermatogenic failure have been published (mainly within regulatory
genes of meiosis), most candidate gene studies have been performed in Asian populations and
either lack validation in replication cohorts or show conflicting results (Table 1). The main reasons
for such inconsistency are (1) the extremely reduced case/control cohort sizes analysed, which
had led most likely to many type I and II errors in statistical hypothesis testing, and (2) the
poor clinical characterisation of the patients included. Replicated associations of NOA-specific
candidate genes include AR (see above) [143,144], PIWIL4 (PIWI-like 4, MIM*610315, encoding a key
molecule for retrotransposon silencing in the germ line) [145–147], MTHFR (methylenetetrahydrofolate
reductase, MIM*607093; an important regulatory gene involved in folate metabolism) [148–150],
MTR (5-methyltetrahydrofolate-homocysteine S-methyltransferase, MIM*156570; responsible for the
regeneration of methionine from homocysteine by transferring of a methyl group) [149,151], NOS3
(nitric oxide synthase 3, MIM*163729; involved in the release of nitric oxide for the regulation of
the reproductive function) [152,153], and H2BFWT (H2B histone family, member W, testis-specific,
MIM*300507, a testis-specific histone variant gene related to spermatogenesis) [154–156].
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Table 1. Common genetic variations associated with nonobstructive azoospermia through association studies.
Year Risk Loci VariantID
Variant
Type
Position
(GRCh38)
Functional
Annotation Population
Cohort Size
(Case/Control) p-Value OR (CI 95%)
Associated
Trait Strategy Reference Replication
1999 AR (CAG)n CNV X: 67545318 Exonic Japanese 41/48 0.0013 NA NOA Candidate gene Yoshida et al. [157] YES
2003 MTHFR rs1801133 SNV 1:11796321 Missense Italian 21/105 NA NA NOA Candidate gene Stuppia et al. [148] YES
2006 MEI1 rs2050033 SNV 22:41763225 Synonymous European/Israeli 26/121 0.027 *,*,*,* NA MA Candidate gene Sato et al. [158] NO
2006 MTR rs1805087 SNV 1:236885200 Missense South Korean 174/325 0.0063 *,* 4.63 (1.40–15.31) NOA Candidate gene Lee et al. [151] YES
2010 PACRG rs9347683 SNV 6:162728023 5′-UTR Australian 206/156 0.009 1.60 (1.13–2.36) NOA Candidate gene Wilson et al. [159] NO
2010 BCL2 rs1800477 SNV 18:63318540 Missense Han Chinese 198/183 0.01 * 0.45 (0.23–0.89) NOA Candidate gene Ma et al. [160] NO
2010 KDM3A rs34605051 SNV 2:86466703 Missense European 80/158 3.23 × 10−3 *,* NA NOA GWAS follow-up Aston et al. [161] NO
2010 TAS2R38 rs10246939 SNV 7:141972804 Missense European 80/158 7.24 × 10−4 * NA NOA GWAS follow-up Aston et al. [161] NO
2011 MTHFR rs1801131 SNV 1:11794419 Missense Brazilian 55/173 0.01 * 0.34 (0.16–0.74) NOA Candidate gene Gava et al. [149] YES
2011 PEX10 rs2477686 SNV 1:2461209 Intergenic Han Chinese 2927/5734 5.65 × 10−12 1.39 (1.26–1.52) NOA GWAS Hu et al. [162] NO
2011 PRMT6 rs12097821 SNV 1:106793679 Intergenic Han Chinese 2927/5734 5.67 × 10−10 1.25 (1.17–1.34) NOA GWAS Hu et al. [162] YES
2011 SOX5 rs10842262 SNV 12:24031610 Intronic Han Chinese 2927/5734 2.32 × 10−9 1.23 (1.15–1.32) NOA GWAS Hu et al. [162] YES
2012 H2BFWT rs7885967 SNV X:104013669 5′-UTR Chinese 204/209 0.001 1.89 (1.28–2.79) NOA Candidate gene Ying et al. [154] YES
2012 HLA-DRA rs3129878 SNV 6:32440958 Intronic Han Chinese 2226/4576 3.70 × 10−16 1.37 (NA) NOA GWAS Zhao et al. [163] YES
2012 TSBP1 rs498422 SNV 6:32318984 Intronic Han Chinese 2226/4576 2.43 × 10−12 1.42 (NA) NOA GWAS Zhao et al. [163] YES
2013 ATM rs189037 SNV 11:108223106 5′-UTR Chinese 229/236 0.003 1.41 (1.11–1.78) NOA Candidate gene Li et al. [164] NO
2013 NOS3 rs2070744 SNV 7:150992991 Intronic Chinese 151/246 <0.001 2.52 (1.56–4.06) NOA Candidate gene Ying et al. [152] YES
2013 NOS3 rs61722009 INDEL 7:150997170 Intronic Chinese 151/246 0.001 2.27 (1.39–3.72) NOA Candidate gene Ying et al. [152] YES
2014 ABLIM1 rs7099208 SNV 10:114894815 Intronic Han Chinese 3608/5909 6.41 × 10−14 1.41(1.29–1.54) NOA GWAS replication Hu et al. [165] YES
2014 BCL2 rs7226979 SNV 18:63257737 Intronic Han Chinese 1653/2329 4.50 × 10−5 1.21 (1.11–1.33) NOA GWAS replication Qin et al. [166] NO
2014 CHD2 rs140671 SNV 15:26976951 Intronic Han Chinese 1653/2329 1.70 × 10−4 0.78 (0.68–0.89) NOA GWAS replication Qin et al. [166] NO
2014 GNAO1 rs2126986 SNV 16:56317795 Intronic Han Chinese 1653/2329 2.30 × 10−6 1.28 (1.15–1.41) NOA GWAS replication Qin et al. [166] NO
2014 HLA-DRA rs7194 SNV 6:32444703 3′-UTR Han Chinese 3608/5909 3.76 × 10−19 1.30 (1.23–1.38) NOA GWAS replication Hu et al. [165] YES
2014 IL17A rs13206743 SNV 6:52152310 Intergenic Han Chinese 3608/5909 3.69 × 10−8 1.35 (1.22–1.51) NOA GWAS replication Hu et al. [165] NO
2014 PIWIL4 rs508485 SNV 11:94621313 3′-UTR Spanish 22/56 0.021 NA MA Candidate gene Muñoz et al. [145] YES
2014 SFRS4 rs12046213 SNV 1:29186811 Intergenic Chinese 962/1931 0.021 0.88 (0.78–0.98) NOA Candidate gene Ni et al. [167] NO
2014 SFRS6 rs6103330 SNV 20:43458814 Intronic Chinese 962/1931 2.78 × 10−3 1.28 (1.09–1.50) NOA Candidate gene Ni et al. [167] NO
2014 SFRS9 rs17431717 SNV 12:120474407 Intronic Chinese 962/1931 0.035 0.73 (0.54–0.98) NOA Candidate gene Ni et al. [167] NO
2014 SFRS9 rs10849753 SNV 12:120473010 Intronic Chinese 962/1931 4.32 × 10−3 1.17 (1.05–1.31) NOA Candidate gene Ni et al. [167] NO
2014 SPO11 rs28368082 SNV 20:57335452 Missense Iranian 58/50 0.006 6.68 (NA) NOA Candidate gene Ghalkhani et al. [168] NO
2015 GSTP1 rs1695 SNV 11:67585218 Missense Chinese 361/234 0.023 * 1.48 (1.06–2.07) NOA Candidate gene Xiong et al. [169] NO
2015 USF1 rs2516838 SNV 1:161044580 Intronic Chinese 361/368 0.02 1.43 (1.06–1.95) NOA Candidate gene Zhang et al. [170] NO
2015 EPSTI1 rs12870438 SNV 13:42906069 Intronic Japanese 76/791 0.0059 1.92 (1.21–3.05) NOA Candidate gene Sato et al. [171] NO
2015 FSHR rs6165 SNV 2:48963902 Missense Iranian 126/86 0.001 2.06 (1.36–3.12) NOA Candidate gene Gharesi-Fard et al. [172] NO
2015 MLH3 rs175080 SNV 14:75047125 Missense Chinese 244/614 <0.001 1.75 (1.27–2.41) NOA Candidate gene Zhang et al. [173] NO
2015 MTHFR rs55763075 SNV 1:11790377 3′-UTR Chinese 253/458 0.043 1.27 (1.01–1.58) NOA Candidate gene Zhang et al. [174] NO
2015 SOHLH2 rs1328626 SNV 13:36204635 Intronic Chinese 361/368 0.038 0.80 (0.65–0.99) NOA Candidate gene Song et al. [175] NO
2015 SOHLH2 rs6563386 SNV 13:36202894 Intronic Chinese 361/368 0.029 1.40 (1.03–1.90) NOA Candidate gene Song et al. [175] NO
2016 HSA-miR-196a rs11614913 SNV 12:53991815 Intergenic Chinese 140/486 0.009 * 1.76 (1.15–2.70) NOA Candidate gene Lu et al. [176] NO
2016 NR3C1 rs852977 SNV 5:143307929 Intronic Japanese 335/410 5.70 × 10−15 3.20 (2.40–4.26) NOA Candidate gene Chihara et al. [177] NO
2016 TDRD1 rs77559927 SNV 10:114179297 5′-UTR Chinese 342/493 0.03 * 0.73 (0.56–0.97) NOA Candidate gene Zhu et al. [178] NO
2016 YBX2 rs222859 SNV 17:7294475 Missense Iranian 60/96 <0.05 *,*,* 0.23 (0.12–0.6) NOA Candidate gene Najafipour et al. [179] NO
2017 CYP1A1 rs4646903 SNV 15:74719300 Intergenic South Indian 120/80 0.0001 * 3.71 (2.05–6.74) NOA Candidate gene Ramgir et al. [180] NO
2017 FASL rs763110 SNV 1:172658358 Intergenic Iranian 102/110 0.02 *,*,* NA NOA Candidate gene Asgari et al. [181] NO
2017 PRKDC rs7003908 SNV 8:47858141 Intronic Iranian 102/214 0.03 1.51 (1.04–2.18) NOA Candidate gene Jahantigh et al. [182] NO
2017 TNFR1 rs767455 SNV 12:6341779 Synonymous Iranian 108/119 <0.001 2.30 (1.58–3.36) NOA Candidate gene Ashrafzadeh et al. [183] NO
2017 XRCC5 rs6147172 VNTR 2:216109147 Promoter Iranian 102/214 0.001 0.43 (0.26–0.73) NOA Candidate gene Jahantigh et al. [182] NO
2017 XRCC6 rs2267437 SNV 22:41620695 Intronic Iranian 102/214 0.0002 1.94 (1.37–2.75) NOA Candidate gene Jahantigh et al. [182] NO
2018 DICER1 rs1057035 SNV 14:95087805 3′-UTR Iranian 135/120 <0.05 1.49 (1.27–1.88) NOA Candidate gene Moghbelinejad et al. [184] NO
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Table 1. Cont.
Year Risk Loci VariantID
Variant
Type
Position
(GRCh38)
Functional
Annotation Population
Cohort Size
(Case/Control) p-Value OR (CI 95%)
Associated
Trait Strategy Reference Replication
2018 DPF3 rs10129954 SNV 14:72683993 Intronic Japanese 83/713 7.40 × 10−3 2.05 (1.21–3.46) NOA Candidate gene Sato et al. [185] NO
2018 H2BFWT rs553509 SNV X:104013293 Missense Iranian 120/250 0.019 1.69 (1.09–2.62) NOA Candidate gene Teimouri et al. [186] NO
2018 IL1A rs2071376 SNV 2:112777818 Intronic Iranian 230/230 0.034 1.67 (1.04–2.68) NOA Candidate gene Zamani-Badi et al. [187] NO
2018 IL1A rs17561 SNV 2:112779646 Missense Iranian 230/230 <0.0001 2.59 (1.67–4.04) NOA Candidate gene Zamani-Badi et al. [188] NO
2018 RNF212 rs4045481 SNV 4:1096837 Synonymous Chinese 220/248 0.003 1.50 (1.15–1.95) NOA Candidate gene Yu et al. [189] NO
2019 ERCC2 rs13181 SNV 19:45351661 Missense Indo-European 541/416 0.03 *,*,*,* 1.59 (1.04–2.42) NOA Candidate gene Singh et al. [190] NO
2019 FSHB rs10835638 SNV 11:30230805 Intergenic German 659 0.017 *,*,*,*,* 0.20 (0.06–0.70) TESE– Candidate gene Busch et al. [191] NO
2019 MSH3 rs26279 SNV 5:80873118 Missense Northwest Chinese 131/201 <0.05 *,* 2.62 (1.05–6.57) NOA Candidate gene Zhao et al. [192] NO
2019 HLA-B rs4997052 SNV 6:31356367 Missense Han Chinese 981/1657 2.26 × 10−5 1.30 (1.15–1.46) NOA GWAS imputation Huang et al. [193] NO
2020 STAG3 rs1727130 SNV 7:100213841 Intronic Korean 77/245 0.039 * 1.64 (1.03–2.61) NOA Candidate gene Nam et al. [194] NO
2020 STAG3 rs1052482 SNV 7:100214213 3′-UTR Korean 77/245 0.039 * 1.64 (1.03–2.61) NOA Candidate gene Nam et al. [194] NO
p-values of the allelic test are shown except for * dominant model of the minor allele; *,* recessive model of the minor allele; *,*,* genotypic (2-df) model; *,*,*,* codominant model; and
*,*,*,*,* TTvsGG. CI, confidence interval; CNV, copy number variant; GWAS, genome-wide association study; INDEL, insertion/deletion variant; MA, meiotic arrest; OR, odds ratio; NOA,
nonobstructive azoospermia; SNV, single-nucleotide variant; TESE–, unsuccessful testicular sperm extraction; UTR, untranslated region; VNTR, variable number tandem repeat.
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4.2. Insights from Large-Scale Genetic Studies
The development of high-throughput genotyping platforms was a breakthrough that allowed
the investigation of the genetic basis of complex traits at a genome-wide level [195]. In particular, the
genome-wide association studies (GWAS), in which genetic variation across the whole genome
is interrogated in a hypothesis-free fashion, have represented a major advance in biomedical
discovery [196]. However, as described below, the GWAS strategy has not been very useful to
define the genetic component of NOA, mainly because of the strong limitations of the study designs.
4.2.1. Pilot GWAS in Europeans
The first GWAS of NOA was conducted in 2009 by Aston and Carrell [197]. In this study, 370,000
SNPs were analysed in 80 patients with spermatogenic impairment (52 with severe oligospermia
and only 40 with NOA) and 80 normozoospermic controls of European descent. Such a small study
cohort implied a statistical power close to zero, which prevented the authors from obtaining any
relevant results. It should be noted that hundreds of thousands of independent tests are conducted
in a GWAS. Hence, a p-value threshold for statistical significance of 5 × 10−8 is required to control
the (highly probable) type I errors in these types of studies [198–200]. Therefore, considerably large
case/control populations are needed to discern disease-specific associations from the numerous false
positive signals. Taking this into consideration, the authors performed a follow-up study in a slightly
larger European population composed of 141 severe oligospermic individuals, 80 NOA patients, 63
moderately oligospermic individuals, and 158 normospermic controls. They analysed 172 candidate
SNPs (based on both gene function and previously published reports of association with male infertility)
and performed a combined analysis with their previous GWAS data [161]. The comparison of the
NOA group against the control one evidenced suggestive associations just for two non-synonymous
SNPs (rs34605051 and rs10246939) of the genes KDM3A (lysine-specific demethylase 3A, MIM* 611512;
a histone demethylase involved in packaging and condensation of sperm chromatin) and TAS2R38
(taste receptor, type 2, member 38, MIM*607751; a surface protein of taste receptor cells with no
reported function in the testis). Other SNPs showed significant P-values when NOA and severe
oligospermia patients were analysed together, including two missense variants of TEX15 (rs323344
and rs323345) [161].
4.2.2. First GWAS in East Asians
The first well-powered GWAS was published in 2011 by Hu et al. [162]. The authors performed
a three-stage study comprising a total of 2927 NOA patients and 5734 control subjects, all from the
Han Chinese population. This study reported the first NOA associations at the genome-wide level of
significance in the genomic regions of PRMT6 (protein arginine N-methyltransferase 6, MIM*608274; a
methyltransferase expressed in spermatogonia), PEX10 (peroxisome biogenesis factor 10, MIM*602859;
a peroxisomal protein potentially involved in spermatogenesis), and SOX5 (SRY-BOX 5, MIM*604975;
encoding a transcription factor restricted to post-meiotic germ cells during spermatogenesis). SOX5
was also associated to oligospermia in a subsequent study [201]. However, the NOA population of
the GWAS included individuals with partial deletions of the AZF region, and the controls were not
healthy (they were obtained from a lung cancer study) and lacked semen analysis, which could have
influenced the final results [162]. Indeed, inconsistent results were obtained in different replication
studies. Whereas the three NOA associations described in the GWAS failed to replicate in a population
of 490 NOA patients and 1167 controls from Japan [202], both the PEX10 and SOX5 risk variants showed
evidence of association with NOA in an independent study cohort from central China composed of
301 azoospermic cases and 720 normal controls [203].
In 2014, aimed to identify additional NOA susceptibility factors, the same group conducted an
extended three-stage validation study of the GWAS in 3608 NOA cases (including the original GWAS
cohort) and 5909 controls from China [165]. Genetic associations at the genome-wide level of significance
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were observed in three new loci: a genomic region near IL17A (interleukin 17A, MIM*603149; encoding
a proinflammatory cytokine), ABLIM1 (actin-binding LIM protein family, member 1, MIM*602330; a
regulatory gene of the actin-dependent signalling), and HLA-DRA (major histocompatibility complex,
class II, DR alpha, MIM*142860; encoding the alpha subunit of the HLA-DR molecule). The two latter
associations were further replicated in independent Chinese populations [204,205].
Another follow-up study of the GWAS was performed by Qin and colleagues in 2014 [166].
The authors obtained imputed genotypes from the original GWAS data and carried out a two-stage
association study of 24,238 makers (selected for their location within genes of canonical pathways
known to be important in spermatogenesis) in a Han Chinese case/control cohort comprising 1653
NOA cases and 2329 controls. The SNPs rs1406714 in CHD2 (chromodomain helicase DNA-binding
protein 2, MIM*602119; which may play a role in the DNA damage response and genome stability
maintenance), rs2126986 in GNAO1 (guanine nucleotide-binding protein, alpha-activating activity
polypeptide O, MIM*139311; a member of guanine nucleotide binding proteins), and rs7226979 in
BCL2 (B-cell CLL/lymphoma 2, MIM* 151430; encoding an apoptosis regulator) were identified as
novel NOA risk variants. However, these associations have not been replicated in independent studies
so far.
4.2.3. Second GWAS in East Asians
A second GWAS of NOA in the Han Chinese population was conducted by Zhao and collaborators
in 2012 [163]. The study followed a three-stage approach, including a total of 2226 NOA cases and 4576
controls. Although the large sample set allowed the authors to perform the analyses with a considerably
high statistical power, almost half of the control cohort included in the first stage was composed of
women, representing an important limitation. Despite this, different association signals within the
HLA region were associated with NOA risk at the genome-wide significance level. The strongest
one corresponded to a haplotype block of the HLA-DRA locus, whose lead variant was rs3129878
(located in intron 1 of the gene). A second independent SNP (rs498422) located in the nearby gene
TSBP1 (testis-expressed basic protein 1, MIM*618151; encoding a protein expressed in the testis with
unknown function) was also detected. The associated HLA variants were described as tag SNPs of
the classical allele HLA-DRB*0405. Therefore, this study highlighted the HLA system as a relevant
player in the development of idiopathic NOA, likely by triggering autoimmune/autoinflammatory
responses against germ cell antigens in pathogenic situations in which the blood–testis barrier could
be damaged [206].
4.2.4. Fine-Mapping of the Major Histocompatibility Complex Region
In a recent study, Huang and colleagues aimed to fine-map the HLA association with NOA
described in the two GWASs of the Han Chinese population [193]. With that purpose, they used a
specific imputation method to infer classical HLA alleles, SNPs, and polymorphic amino acid positions
using the data of the extended HLA region from the GWAS by Hu et al. [162]. The most statistically
significant classical haplotype was HLA Class II HLA-DRB1*13:02, which had been reported before as
an NOA risk allele in the Japanese population [207]. Additionally, two SNPs explained most of the
HLA association with NOA, i.e., the HLA-DRA polymorphism rs7194 (reported as putative association
marker in the two original GWASs) and the HLA-B polymorphism rs4997052, which represented a
novel risk variant for NOA. The authors estimated that the proportion of phenotypic variance of NOA
explained by these two HLA SNPs and the one established in the GWAS by Zhao [163] was between
0.5% and 1%. Regarding the analysis at the amino acid level, position 55 of the HLA-DQB1 molecule
represented the most statistically significant multiallelic site (Figure 2). Three possible residues were
detected at that position: one of them representing a risk residue (arginine), another one representing a
protective residue (leucine), and the third one with no effect on the susceptibility to NOA (proline).
Other independently associated amino acid positions were HLA-DRB1*73 (with glycine conferring the
higher risk) and HLA-B*166 (serine being the strongest risk residue).
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Figure 2. Ribbon representation of the HLA-DQ molecule. The most associated amino acid position
with nonobstructive azoospermia susceptibility is highlighted with a red sphere. P-values, odds ratios
(ORs), and the effect conferred by the different residues at that position are also shown. Data obtained
from Huang et al. [193].
4.2.5. GWAS in Hutterites
Also in 2012, a GWAS of male infertility was performed in Hutterites (a North American
ethnoreligious group of European ancestry that has large family sizes because contraception is
proscribed) by Kosova and colleagues [208]. The authors tested for association with two heritable
measures of fertility, family size and birth rate, in a random population of 269 married men. To validate
the GWAS results, the most highly associated SNPs were genotyped in an independent population of
123 ethnically diverse male individuals from Chicago. However, because of the reduced statistical
power of the study, no associated SNPs at the genome-wide level of significance were identified.
Subsequent candidate gene studies in Japanese were designed to evaluate the possible association
with NOA susceptibility of the suggestive signals observed in the GWAS of the Hutterite population
(those with P-values lower than 1 × 10−4). The first of them was performed in 2015 and included a total
of 917 Japanese subjects (76 NOA patients, 50 patients with oligospermia, and 791 fertile men) [171].
Interestingly, an intronic variant of EPSTI1 (epithelial stromal interaction 1, MIM*607441; encoding the
epithelial stromal interaction protein 1, which is highly expressed in the testis) was associated with
NOA at the study-wide level of significance after correction for multiple testing. The second study
was also conducted by the same team three years later using the same case/control cohort [185]. In
this case, a significant association was observed between an intronic variant of DPF3 (D4, zinc, and
double PHD fingers family, member 3, MIM*601672; a transcription regulator involved in chromatin
remodelling) and NOA risk.
4.2.6. Other Genome-Wide Approaches
Other large-scale approaches have been followed during the last years to shed light into the
molecular causes of idiopathic NOA, including (1) an exome-wide association study that described
three rare variants associated with NOA in the chromosome 6 genes HIST1H1E (histone gene cluster 1,
H1 histone family, member E; MIM*142220; encoding the linker histone H1.4), FKBPL (FK506-binding
protein-like, MIM*617076; which is involved in the steroid hormone signalling), and MSH5 (MutS
homolog 5, MIM*603382; which plays a role in meiotic segregation fidelity and recombination) [209];
(2) different comparative genomic hybridization (CGH) studies that identified NOA-specific recurrent
CNVs such as CNV67 (on Xq28), with potential clinical application [109,210–213]; (3) miRNA profiling
in the seminal plasma, in which miR-141, miR-429, and miR-7-1-3p were significantly increased in
NOA patients compared with fertile controls [214]; (4) a transcriptome-wide association study that
established PILRA (paired immunoglobulin-like type 2 receptor, alpha, MIM*605341; potentially
involved in the regulation of spermatogenesis and the blood–testis barrier) and ZNF676 (zinc finger
protein 676; which may regulate the expression of genes associated with germ cell development) as
putative novel NOA genes [215]; and (5) two genome-wide DNA methylation studies that identified
NOA-specific methylation profiles in testicular tissues, including hyper-methylation of SOX30 (SRY-box
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30, MIM*606698; encoding an essential transcription factor for spermiogenesis) at the gene promoter,
thus providing insight into the mechanisms underlying idiopathic NOA [216,217].
5. Clinical Relevance of the Genetic Studies of Nonobstructive Azoospermia
The rapid improvement of the new technologies for genetic analysis has enabled a substantial
increase in our understanding of the aetiology of male infertility. However, the impact of such
knowledge in the current genetic workup of azoospermic men is still limited, with very few novel
findings incorporated to the genetic tests routinely used in clinical practice during the last two
decades [24]. A genetic cause is normally identified in only 4% of infertile men, but this percentage
increases to about 20% in azoospermic patients, thus highlighting the important contribution of genetic
factors in the development of the most severe forms of male infertility [76]. This genetic influence is
likely more relevant in NOA patients whose infertility causes remain idiopathic despite extensive
laboratory evaluation.
As summarised above, increasing evidence points to idiopathic NOA as a complex and highly
polygenic condition [218]. Because of that, the elucidation of its genetic component is highly demanded
by thousands of urologists who have to deal with this condition on a day-to-day basis, as it may
facilitate an appropriate clinical decision for enhancing fertility. Nevertheless, about 2000 genes have
been proposed to be directly involved in the spermatogenic process, with more than 600 of them
showing a specific expression in male germ cells [19,219–221]. This fact makes it extremely difficult to
visualize the overall molecular picture of azoospermia, leading some authors to be skeptical about the
feasibility of translating molecular genetic insights into clinical practice, especially those related to
common variations of the human genome [10,222,223].
Hopefully, a more optimistic scenario will be envisioned soon. There are some promising
preliminary results supporting the important role that genetic testing may have in improving both
care and counselling of patients diagnosed with idiopathic NOA [9]. For instance, Tüttelmann and
colleagues have recently started to regularly analyse the gene sequence of NR5A1, DMRT1, and TEX11
in patients with idiopathic NOA, identifying causal pathogenic mutations in 5% of them and increasing
the diagnostic efficiency to 25% in their study group [76]. In this sense, identifying a higher proportion
of the heritability of spermatogenic impairment would definitively allow the development of broader
diagnostic panels of genes, which could help (1) to achieve an accurate diagnosis, (2) to improve the
selection criteria of spermatozoa for successful assisted reproduction techniques, reducing the possible
genetic burden transmitted to the offspring, and (3) to estimate reliable personalized genetic scores
with a prognostic value before counselling a patients to undergo testicular sperm retrieval or endocrine
therapy [23,224].
6. Conclusions
The development and widespread use of novel tools for genetic analysis has represented a turning
point in the investigation of the genetic component of male infertility. In relation to NOA, the impact
has been remarkable because azoospermic individuals are at the highest risk of harbouring genetic
abnormalities. Consequently, many point mutations explaining specific cases of azoospermia are being
increasingly reported, including paternal and de novo mutations in key genes involved in the testicular
function. However, recent estimations suggest that around 75% of cases with severe spermatogenic
impairment have an idiopathic origin [225]. In this regard, as discussed in this review, different
lines of evidence suggest that, apart from those point mutations (which represent undoubtedly a
primary cause of NOA in many patients), common variations of the human genome, mostly SNPs and
CNVs, may also have a role in the development of pathogenic mechanisms leading to spermatogenic
failure. The concerns of some authors about this assumption rely on the inconsistency of some
results obtained from case/control association studies. Nevertheless, it should be noted that NOA is
a very heterogeneous condition, comprising different clinical entities (such as SCO, meiotic arrest,
and hypospermatogenesis) with specific histological patterns and probably distinct aetiologies. This
J. Clin. Med. 2020, 9, 300 16 of 27
makes essential to establish stringent selection criteria for the study cohorts, which has not been
possible in most studies. Besides, a low statistical power has represented an important limitation
in the case/control analyses, especially in GWAS, which require considerably large sample sets to
avoid type II errors. Therefore, it is imperative to reach a broad consensus on which clinical entities
of NOA can be analysed in more homogeneous study groups. Certainly, this would require the
establishment of large collaborative consortia that can join forces gathering well-powered case/control
cohorts. Considering the current advances in assisted reproductive techniques, with most natural
barriers for in vitro fertilisation and intracytoplasmic sperm injection being overcome, we need to
focus now on identifying the pieces of the genetic puzzle of male infertility, which may include not
only genes involved in testicular spermatogenesis, but also countless additional genes with roles in
sperm maturation after exit from testes during epididymal passage. The development of effective
genetic diagnostic and prognostic markers would be essential for counselling NOA patients with
concerns about the causes of their infertility, the probability of success of testis sperm retrieval and
in vitro fertilization, as well as the potential reproductive health of their children.
Author Contributions: Writing—Review and Editing, M.C., F.D.C., and R.P.; Visualization, F.D.C., R.P., and J.A.C.;
Supervision, F.D.C. and R.P.; Project Administration, F.D.C., R.P., and J.A.C. All authors have read and agreed to
the published version of the manuscript.
Acknowledgments: We thank Alejandro Fernández Sevilla for his valuable help in the development of Figure 2
of this review. The authors were funded by the Spanish Ministry of Economy and Competitiveness through
the Spanish National Plan for Scientific and Technical Research and Innovation (ref. SAF2016-78722-R) and the
“Ramón y Cajal” program (ref. RYC-2014-16458).
Conflicts of Interest: The authors declare no conflicts of interest.
References
1. Mascarenhas, M.N.; Flaxman, S.R.; Boerma, T.; Vanderpoel, S.; Stevens, G.A. National, regional, and global
trends in infertility prevalence since 1990: A systematic analysis of 277 health surveys. PLoS Med. 2012, 9,
e1001356. [CrossRef] [PubMed]
2. Chandra, A.; Copen, C.E.; Stephen, E.H. Infertility and impaired fecundity in the United States, 1982–2010:
Data from the National Survey of Family Growth. Natl. Health Stat. Rep. 2013, 67, 1–18.
3. Jarow, J.P.; Espeland, M.A.; Lipshultz, L.I. Evaluation of the azoospermic patient. J. Urol. 1989, 142, 62–65.
[CrossRef]
4. Thonneau, P.; Marchand, S.; Tallec, A.; Ferial, M.L.; Ducot, B.; Lansac, J.; Lopes, P.; Tabaste, J.M.; Spira, A.
Incidence and main causes of infertility in a resident population (1,850,000) of three French regions (1988–1989).
Hum. Reprod. 1991, 6, 811–816. [CrossRef] [PubMed]
5. Mazzilli, F.; Rossi, T.; Delfino, M.; Sarandrea, N.; Dondero, F. Azoospermia: Incidence, and biochemical
evaluation of seminal plasma by the differential pH method. Panminerva Med. 2000, 42, 27–31. [PubMed]
6. Tuttelmann, F.; Werny, F.; Cooper, T.G.; Kliesch, S.; Simoni, M.; Nieschlag, E. Clinical experience with
azoospermia: Aetiology and chances for spermatozoa detection upon biopsy. Int. J. Androl. 2011, 34, 291–298.
[CrossRef] [PubMed]
7. Agarwal, A.; Mulgund, A.; Hamada, A.; Chyatte, M.R. A unique view on male infertility around the globe.
Reprod. Biol. Endocrinol. 2015, 13, 37. [CrossRef]
8. Esteves, S.C. Clinical management of infertile men with nonobstructive azoospermia. Asian J. Androl. 2015,
17, 459–470. [CrossRef]
9. Tournaye, H.; Krausz, C.; Oates, R.D. Novel concepts in the aetiology of male reproductive impairment.
Lancet Diabetes Endocrinol. 2017, 5, 544–553. [CrossRef]
10. Krausz, C.; Riera-Escamilla, A. Genetics of male infertility. Nat. Rev. Urol. 2018, 15, 369–384. [CrossRef]
11. Brennan, J.; Capel, B. One tissue, two fates: Molecular genetic events that underlie testis versus ovary
development. Nat. Rev. Genet. 2004, 5, 509–521. [CrossRef] [PubMed]
12. Phillips, B.T.; Gassei, K.; Orwig, K.E. Spermatogonial stem cell regulation and spermatogenesis. Philos. Trans.
R. Soc. B Biol. Sci. 2010, 365, 1663–1678. [CrossRef] [PubMed]
J. Clin. Med. 2020, 9, 300 17 of 27
13. Potter, S.J.; DeFalco, T. Role of the testis interstitial compartment in spermatogonial stem cell function.
Reproduction 2017, 153, R151–R162. [CrossRef] [PubMed]
14. Wu, S.; Yan, M.; Ge, R.; Cheng, C.Y. Crosstalk between Sertoli and Germ Cells in Male Fertility. Trends Mol.
Med. 2019. [CrossRef]
15. Fayomi, A.P.; Orwig, K.E. Spermatogonial stem cells and spermatogenesis in mice, monkeys and men. Stem
Cell Res. 2018, 29, 207–214. [CrossRef]
16. Larose, H.; Shami, A.N.; Abbott, H.; Manske, G.; Lei, L.; Hammoud, S.S. Gametogenesis: A journey from
inception to conception. Curr. Top. Dev. Biol. 2019, 132, 257–310.
17. Shiraishi, K. Hormonal therapy for non-obstructive azoospermia: Basic and clinical perspectives. Reprod.
Med. Biol. 2015, 14, 65–72. [CrossRef]
18. Younes, A.H.; Hamed, H.B.; Mohamed, E.M.; Makki, M.A.; Gaber, N.; Mohamed, H.M. Oestrogen receptors
beta genotype in infertile Egyptian men with nonobstructive azoospermia. Andrologia 2016, 48, 1289–1293.
[CrossRef]
19. Schultz, N.; Hamra, F.K.; Garbers, D.L. A multitude of genes expressed solely in meiotic or postmeiotic
spermatogenic cells offers a myriad of contraceptive targets. Proc. Natl. Acad. Sci. USA 2003, 100, 12201–12206.
[CrossRef]
20. Gunes, S.; Al-Sadaan, M.; Agarwal, A. Spermatogenesis, DNA damage and DNA repair mechanisms in male
infertility. Reprod. Biomed. Online 2015, 31, 309–319. [CrossRef]
21. Robles, V.; Herraez, P.; Labbe, C.; Cabrita, E.; Psenicka, M.; Valcarce, D.G.; Riesco, M.F. Molecular basis of
spermatogenesis and sperm quality. Gen. Comp. Endocrinol. 2017, 245, 5–9. [CrossRef] [PubMed]
22. Jungwirth, A.; Giwercman, A.; Tournaye, H.; Diemer, T.; Kopa, Z.; Dohle, G.; Krausz, C.; European
Association of Urology Working Group on Male Infertility. European Association of Urology guidelines on
Male Infertility: The 2012 update. Eur. Urol. 2012, 62, 324–332. [CrossRef] [PubMed]
23. Berookhim, B.M.; Schlegel, P.N. Azoospermia due to spermatogenic failure. Urol. Clin. N. Am. 2014, 41,
97–113. [CrossRef] [PubMed]
24. Barratt, C.L.R.; Bjorndahl, L.; De Jonge, C.J.; Lamb, D.J.; Osorio Martini, F.; McLachlan, R.; Oates, R.D.; van
der Poel, S.; St John, B.; Sigman, M.; et al. The diagnosis of male infertility: An analysis of the evidence
to support the development of global WHO guidance-challenges and future research opportunities. Hum.
Reprod. Update 2017, 23, 660–680. [CrossRef]
25. Palermo, G.D.; Colombero, L.T.; Hariprashad, J.J.; Schlegel, P.N.; Rosenwaks, Z. Chromosome analysis of
epididymal and testicular sperm in azoospermic patients undergoing ICSI. Hum. Reprod. 2002, 17, 570–575.
[CrossRef]
26. Chandley, A.C. Infertility and chromosome abnormality. Oxf. Rev. Reprod. Biol. 1984, 6, 1–46.
27. Rivas, F.; Garcia-Esquivel, L.; Diaz, M.; Rivera, H.; Cantu, J.M. Cytogenetic evaluation of 163 azoospermics. J.
Genet. Hum. 1987, 35, 291–298.
28. Yatsenko, A.N.; Yatsenko, S.A.; Weedin, J.W.; Lawrence, A.E.; Patel, A.; Peacock, S.; Matzuk, M.M.; Lamb, D.J.;
Cheung, S.W.; Lipshultz, L.I. Comprehensive 5-year study of cytogenetic aberrations in 668 infertile men. J.
Urol. 2010, 183, 1636–1642. [CrossRef]
29. Bojesen, A.; Gravholt, C.H. Klinefelter syndrome in clinical practice. Nat. Clin. Pract. Urol. 2007, 4, 192–204.
[CrossRef]
30. Denschlag, D.; Tempfer, C.; Kunze, M.; Wolff, G.; Keck, C. Assisted reproductive techniques in patients with
Klinefelter syndrome: A critical review. Fertil. Steril. 2004, 82, 775–779. [CrossRef]
31. Tiepolo, L.; Zuffardi, O. Localization of factors controlling spermatogenesis in the nonfluorescent portion of
the human Y chromosome long arm. Hum. Genet. 1976, 34, 119–124. [CrossRef] [PubMed]
32. Vogt, P.H.; Edelmann, A.; Kirsch, S.; Henegariu, O.; Hirschmann, P.; Kiesewetter, F.; Köhn, F.M.; Schill, W.B.;
Farah, S.; Ramos, C.; et al. Human Y chromosome azoospermia factors (AZF) mapped to different subregions
in Yq11. Hum. Mol. Genet. 1996, 5, 933–943. [CrossRef] [PubMed]
33. Ma, K.; Sharkey, A.; Kirsch, S.; Vogt, P.; Keil, R.; Hargreave, T.B.; McBeath, S.; Chandley, A.C. Towards
the molecular localisation of the AZF locus: Mapping of microdeletions in azoospermic men within 14
subintervals of interval 6 of the human Y chromosome. Hum. Mol. Genet. 1992, 1, 29–33. [CrossRef]
[PubMed]
J. Clin. Med. 2020, 9, 300 18 of 27
34. Repping, S.; Skaletsky, H.; Lange, J.; Silber, S.; Van Der Veen, F.; Oates, R.D.; Page, D.C.; Rozen, S.
Recombination between palindromes P5 and P1 on the human Y chromosome causes massive deletions and
spermatogenic failure. Am. J. Hum. Genet. 2002, 71, 906–922. [CrossRef] [PubMed]
35. Krausz, C.; Casamonti, E. Spermatogenic failure and the Y chromosome. Hum. Genet. 2017, 136, 637–655.
[CrossRef] [PubMed]
36. Kamp, C.; Hirschmann, P.; Voss, H.; Huellen, K.; Vogt, P.H. Two long homologous retroviral sequence blocks
in proximal Yq11 cause AZFa microdeletions as a result of intrachromosomal recombination events. Hum.
Mol. Genet. 2000, 9, 2563–2572. [CrossRef]
37. Blanco, P.; Shlumukova, M.; Sargent, C.A.; Jobling, M.A.; Affara, N.; Hurles, M.E. Divergent outcomes of
intrachromosomal recombination on the human Y chromosome: Male infertility and recurrent polymorphism.
J. Med. Genet. 2000, 37, 752–758. [CrossRef]
38. Sun, C.; Skaletsky, H.; Rozen, S.; Gromoll, J.; Nieschlag, E.; Oates, R.; Page, D.C. Deletion of azoospermia
factor a (AZFa) region of human Y chromosome caused by recombination between HERV15 proviruses.
Hum. Mol. Genet. 2000, 9, 2291–2296. [CrossRef]
39. Kuroda-Kawaguchi, T.; Skaletsky, H.; Brown, L.G.; Minx, P.J.; Cordum, H.S.; Waterston, R.H.; Wilson, R.K.;
Silber, S.; Oates, R.; Rozen, S.; et al. The AZFc region of the Y chromosome features massive palindromes
and uniform recurrent deletions in infertile men. Nat. Genet. 2001, 29, 279–286. [CrossRef]
40. Lo Giacco, D.; Chianese, C.; Sanchez-Curbelo, J.; Bassas, L.; Ruiz, P.; Rajmil, O.; Sarquella, J.; Vives, A.;
Ruiz-Castañé, E.; Oliva, R.; et al. Clinical relevance of Y-linked CNV screening in male infertility: New
insights based on the 8-year experience of a diagnostic genetic laboratory. Eur. J. Hum. Genet. 2014, 22,
754–761. [CrossRef]
41. Ginalski, K.; Rychlewski, L.; Baker, D.; Grishin, N.V. Protein structure prediction for the male-specific region
of the human Y chromosome. Proc. Natl. Acad. Sci. USA 2004, 101, 2305–2310. [CrossRef] [PubMed]
42. D’Andrea, A.; Pellman, D. Deubiquitinating enzymes: A new class of biological regulators. Crit. Rev.
Biochem. Mol. Biol. 1998, 33, 337–352. [CrossRef] [PubMed]
43. Vogt, P.H.; Falcao, C.L.; Hanstein, R.; Zimmer, J. The AZF proteins. Int. J. Androl. 2008, 31, 383–394.
[CrossRef] [PubMed]
44. Qureshi, S.J.; Ross, A.R.; Ma, K.; Cooke, H.J.; Intyre, M.A.; Chandley, A.C.; Hargreave, T.B. Polymerase
chain reaction screening for Y chromosome microdeletions: A first step towards the diagnosis of
genetically-determined spermatogenic failure in men. Mol. Hum. Reprod. 1996, 2, 775–779. [CrossRef]
[PubMed]
45. Brown, G.M.; Furlong, R.A.; Sargent, C.A.; Erickson, R.P.; Longepied, G.; Mitchell, M.; Jones, M.H.;
Hargreave, T.B.; Cooke, H.J.; Affara, N.A. Characterisation of the coding sequence and fine mapping of the
human DFFRY gene and comparative expression analysis and mapping to the Sxrb interval of the mouse Y
chromosome of the Dffry gene. Hum. Mol. Genet. 1998, 7, 97–107. [CrossRef] [PubMed]
46. Krausz, C.; Degl’Innocenti, S.; Nuti, F.; Morelli, A.; Felici, F.; Sansone, M.; Varriale, G.; Forti, G. Natural
transmission of USP9Y gene mutations: A new perspective on the role of AZFa genes in male fertility. Hum.
Mol. Genet. 2006, 15, 2673–2681. [CrossRef]
47. Nuti, F.; Krausz, C. Gene polymorphisms/mutations relevant to abnormal spermatogenesis. Reprod. Biomed.
Online 2008, 16, 504–513. [CrossRef]
48. Tyler-Smith, C.; Krausz, C. The will-o’-the-wisp of genetics–hunting for the azoospermia factor gene. N.
Engl. J. Med. 2009, 360, 925–927. [CrossRef]
49. Vogt, P.H. Azoospermia factor (AZF) in Yq11: Towards a molecular understanding of its function for human
male fertility and spermatogenesis. Reprod. Biomed. Online 2005, 10, 81–93. [CrossRef]
50. Mohr, S.; Stryker, J.M.; Lambowitz, A.M. A DEAD-box protein functions as an ATP-dependent RNA
chaperone in group I intron splicing. Cell 2002, 109, 769–779. [CrossRef]
51. Ditton, H.J.; Zimmer, J.; Kamp, C.; Rajpert-De Meyts, E.; Vogt, P.H. The AZFa gene DBY (DDX3Y) is widely
transcribed but the protein is limited to the male germ cells by translation control. Hum. Mol. Genet. 2004,
13, 2333–2341. [CrossRef]
52. Jaroszynski, L.; Zimmer, J.; Fietz, D.; Bergmann, M.; Kliesch, S.; Vogt, P.H. Translational control of the AZFa
gene DDX3Y by 5’UTR exon-T extension. Int. J. Androl. 2011, 34, 313–326. [CrossRef]
J. Clin. Med. 2020, 9, 300 19 of 27
53. Sekiguchi, T.; Iida, H.; Fukumura, J.; Nishimoto, T. Human DDX3Y, the Y-encoded isoform of RNA helicase
DDX3, rescues a hamster temperature-sensitive ET24 mutant cell line with a DDX3X mutation. Exp. Cell Res.
2004, 300, 213–222. [CrossRef] [PubMed]
54. Rauschendorf, M.A.; Zimmer, J.; Ohnmacht, C.; Vogt, P.H. DDX3X, the X homologue of AZFa gene DDX3Y,
expresses a complex pattern of transcript variants only in the male germ line. Mol. Hum. Reprod. 2014, 20,
1208–1222. [CrossRef]
55. Lahn, B.T.; Page, D.C. Functional coherence of the human Y chromosome. Science 1997, 278, 675–680.
[CrossRef]
56. Mitchell, S.F.; Lorsch, J.R. Should I stay or should I go? Eukaryotic translation initiation factors 1 and 1A
control start codon recognition. J. Biol. Chem. 2008, 283, 27345–27349. [CrossRef]
57. Kleiman, S.E.; Yogev, L.; Hauser, R.; Botchan, A.; Maymon, B.B.; Paz, G.; Yavetz, H. Expression profile of
AZF genes in testicular biopsies of azoospermic men. Hum. Reprod. 2007, 22, 151–158. [CrossRef]
58. Nygard, O.; Nika, H. Identification by RNA-protein cross-linking of ribosomal proteins located at the
interface between the small and the large subunits of mammalian ribosomes. EMBO J. 1982, 1, 357–362.
[CrossRef]
59. Andres, O.; Kellermann, T.; Lopez-Giraldez, F.; Rozas, J.; Domingo-Roura, X.; Bosch, M. RPS4Y gene family
evolution in primates. BMC Evol. Biol. 2008, 8, 142. [CrossRef]
60. Skaletsky, H.; Kuroda-Kawaguchi, T.; Minx, P.J.; Cordum, H.S.; Hillier, L.; Brown, L.G.; Repping, S.;
Pyntikova, T.; Ali, J.; Bieri, T.; et al. The male-specific region of the human Y chromosome is a mosaic of
discrete sequence classes. Nature 2003, 423, 825–837. [CrossRef]
61. Lopes, A.M.; Miguel, R.N.; Sargent, C.A.; Ellis, P.J.; Amorim, A.; Affara, N.A. The human RPS4 paralogue
on Yq11.223 encodes a structurally conserved ribosomal protein and is preferentially expressed during
spermatogenesis. BMC Mol. Biol. 2010, 11, 33. [CrossRef]
62. Bernstein, B.E.; Meissner, A.; Lander, E.S. The mammalian epigenome. Cell 2007, 128, 669–681. [CrossRef]
63. Liu, X.; Secombe, J. The Histone Demethylase KDM5 Activates Gene Expression by Recognizing Chromatin
Context through Its PHD Reader Motif. Cell Rep. 2015, 13, 2219–2231. [CrossRef]
64. Mizukami, H.; Kim, J.D.; Tabara, S.; Lu, W.; Kwon, C.; Nakashima, M.; Fukamizu, A. KDM5D-mediated
H3K4 demethylation is required for sexually dimorphic gene expression in mouse embryonic fibroblasts. J.
Biochem. 2019, 165, 335–342. [CrossRef]
65. Blair, L.P.; Cao, J.; Zou, M.R.; Sayegh, J.; Yan, Q. Epigenetic Regulation by Lysine Demethylase 5 (KDM5)
Enzymes in Cancer. Cancers 2011, 3, 1383–1404. [CrossRef]
66. Akimoto, C.; Kitagawa, H.; Matsumoto, T.; Kato, S. Spermatogenesis-specific association of SMCY and MSH5.
Genes Cells Devoted Mol. Cell. Mech. 2008, 13, 623–633. [CrossRef]
67. Navarro-Costa, P.; Plancha, C.E.; Goncalves, J. Genetic dissection of the AZF regions of the human Y
chromosome: Thriller or filler for male (in)fertility? J. Biomed. Biotechnol. 2010, 2010, 936569. [CrossRef]
68. Bhowmick, B.K.; Satta, Y.; Takahata, N. The origin and evolution of human ampliconic gene families and
ampliconic structure. Genome Res. 2007, 17, 441–450. [CrossRef]
69. Repping, S.; van Daalen, S.K.; Brown, L.G.; Korver, C.M.; Lange, J.; Marszalek, J.D.; Pyntikova, T.; van der
Veen, F.; Skaletsky, H.; Page, D.C.; et al. High mutation rates have driven extensive structural polymorphism
among human Y chromosomes. Nat. Genet. 2006, 38, 463–467. [CrossRef]
70. Page, D.C. 2003 Curt Stern Award address. On low expectation exceeded; or, the genomic salvation of the Y
chromosome. Am. J. Hum. Genet. 2004, 74, 399–402. [CrossRef]
71. Seboun, E.; Barbaux, S.; Bourgeron, T.; Nishi, S.; Agulnik, A.; Egashira, M.; Nikkawa, N.; Bishop, C.;
Fellous, M.; McElreavey, K.; et al. Gene sequence, localization, and evolutionary conservation of DAZLA, a
candidate male sterility gene. Genomics 1997, 41, 227–235. [CrossRef]
72. Saxena, R.; de Vries, J.W.; Repping, S.; Alagappan, R.K.; Skaletsky, H.; Brown, L.G.; Ma, P.; Chen, E.;
Hoovers, J.M.; Page, D.C. Four DAZ genes in two clusters found in the AZFc region of the human Y
chromosome. Genomics 2000, 67, 256–267. [CrossRef]
73. Kato, Y.; Katsuki, T.; Kokubo, H.; Masuda, A.; Saga, Y. Dazl is a target RNA suppressed by mammalian
NANOS2 in sexually differentiating male germ cells. Nat. Commun. 2016, 7, 11272. [CrossRef]
74. Ruggiu, M.; Speed, R.; Taggart, M.; McKay, S.J.; Kilanowski, F.; Saunders, P.; Dorin, J.; Cooke, H.J. The mouse
Dazla gene encodes a cytoplasmic protein essential for gametogenesis. Nature 1997, 389, 73–77. [CrossRef]
J. Clin. Med. 2020, 9, 300 20 of 27
75. Oud, M.S.; Volozonoka, L.; Smits, R.M.; Vissers, L.; Ramos, L.; Veltman, J.A. A systematic review and
standardized clinical validity assessment of male infertility genes. Hum. Reprod. 2019, 34, 932–941. [CrossRef]
76. Tuttelmann, F.; Ruckert, C.; Ropke, A. Disorders of spermatogenesis: Perspectives for novel genetic
diagnostics after 20 years of unchanged routine. Med. Genet. 2018, 30, 12–20. [CrossRef]
77. Callewaert, L.; Christiaens, V.; Haelens, A.; Verrijdt, G.; Verhoeven, G.; Claessens, F. Implications of a
polyglutamine tract in the function of the human androgen receptor. Biochem. Biophys. Res. Commun. 2003,
306, 46–52. [CrossRef]
78. Roy, A.K.; Lavrovsky, Y.; Song, C.S.; Chen, S.; Jung, M.H.; Velu, N.K.; Bi, B.Y.; Chatterjee, B. Regulation of
androgen action. Vitam. Horm. 1999, 55, 309–352.
79. McLachlan, R.I.; Wreford, N.G.; O’Donnell, L.; de Kretser, D.M.; Robertson, D.M. The endocrine regulation
of spermatogenesis: Independent roles for testosterone and FSH. J. Endocrinol. 1996, 148, 1–9. [CrossRef]
80. Gottlieb, B.; Beitel, L.K.; Nadarajah, A.; Paliouras, M.; Trifiro, M. The androgen receptor gene mutations
database: 2012 update. Hum. Mutat. 2012, 33, 887–894. [CrossRef]
81. Yeh, S.; Tsai, M.Y.; Xu, Q.; Mu, X.M.; Lardy, H.; Huang, K.E.; Lin, H.; Yeh, S.D.; Altuwaijri, S.; Zhou, X.; et al.
Generation and characterization of androgen receptor knockout (ARKO) mice: An in vivo model for the
study of androgen functions in selective tissues. Proc. Natl. Acad. Sci. USA 2002, 99, 13498–13503. [CrossRef]
82. De Gendt, K.; Swinnen, J.V.; Saunders, P.T.; Schoonjans, L.; Dewerchin, M.; Devos, A.; Tan, K.; Atanassova, N.;
Claessens, F.; Lécureuil, C.; et al. A Sertoli cell-selective knockout of the androgen receptor causes
spermatogenic arrest in meiosis. Proc. Natl. Acad. Sci. USA 2004, 101, 1327–1332. [CrossRef]
83. Edwards, A.; Hammond, H.A.; Jin, L.; Caskey, C.T.; Chakraborty, R. Genetic variation at five trimeric and
tetrameric tandem repeat loci in four human population groups. Genomics 1992, 12, 241–253. [CrossRef]
84. Tut, T.G.; Ghadessy, F.J.; Trifiro, M.A.; Pinsky, L.; Yong, E.L. Long polyglutamine tracts in the androgen
receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J.
Clin. Endocrinol. Metab. 1997, 82, 3777–3782. [CrossRef]
85. Krausz, C.; Escamilla, A.R.; Chianese, C. Genetics of male infertility: From research to clinic. Reproduction
2015, 150, R159–R174. [CrossRef]
86. Davis-Dao, C.A.; Tuazon, E.D.; Sokol, R.Z.; Cortessis, V.K. Male infertility and variation in CAG repeat length
in the androgen receptor gene: A meta-analysis. J. Clin. Endocrinol. Metab. 2007, 92, 4319–4326. [CrossRef]
87. Westerveld, H.; Visser, L.; Tanck, M.; van der Veen, F.; Repping, S. CAG repeat length variation in the
androgen receptor gene is not associated with spermatogenic failure. Fertil. Steril. 2008, 89, 253–259.
[CrossRef]
88. Mangelsdorf, D.J.; Thummel, C.; Beato, M.; Herrlich, P.; Schutz, G.; Umesono, K.; Blumberg, B.; Kastner, P.;
Mark, M.; Chambon, P.; et al. The nuclear receptor superfamily: The second decade. Cell 1995, 83, 835–839.
[CrossRef]
89. Ikeda, Y.; Lala, D.S.; Luo, X.; Kim, E.; Moisan, M.P.; Parker, K.L. Characterization of the mouse FTZ-F1 gene,
which encodes a key regulator of steroid hydroxylase gene expression. Mol. Endocrinol. 1993, 7, 852–860.
90. Morohashi, K.; Iida, H.; Nomura, M.; Hatano, O.; Honda, S.; Tsukiyama, T.; Niwa, O.; Hara, T.; Takakusu, A.;
Shibata, Y.; et al. Functional difference between Ad4BP and ELP, and their distributions in steroidogenic
tissues. Mol. Endocrinol. 1994, 8, 643–653.
91. Barnhart, K.M.; Mellon, P.L. The orphan nuclear receptor, steroidogenic factor-1, regulates the glycoprotein
hormone alpha-subunit gene in pituitary gonadotropes. Mol. Endocrinol. 1994, 8, 878–885. [PubMed]
92. Ingraham, H.A.; Lala, D.S.; Ikeda, Y.; Luo, X.; Shen, W.H.; Nachtigal, M.W.; Abbud, R.; Nilson, J.H.;
Parker, K.L. The nuclear receptor steroidogenic factor 1 acts at multiple levels of the reproductive axis. Genes
Dev. 1994, 8, 2302–2312. [CrossRef] [PubMed]
93. Shinoda, K.; Lei, H.; Yoshii, H.; Nomura, M.; Nagano, M.; Shiba, H.; Sasaki, H.; Osawa, Y.; Ninomiya, Y.;
Niwa, O.; et al. Developmental defects of the ventromedial hypothalamic nucleus and pituitary gonadotroph
in the Ftz-F1 disrupted mice. Dev. Dyn. 1995, 204, 22–29. [CrossRef]
94. Luo, X.; Ikeda, Y.; Parker, K.L. A cell-specific nuclear receptor is essential for adrenal and gonadal development
and sexual differentiation. Cell 1994, 77, 481–490. [CrossRef]
95. Jameson, J.L. Of mice and men: The tale of steroidogenic factor-1. J. Clin. Endocrinol. Metab. 2004, 89,
5927–5929. [CrossRef]
J. Clin. Med. 2020, 9, 300 21 of 27
96. Sadovsky, Y.; Crawford, P.A.; Woodson, K.G.; Polish, J.A.; Clements, M.A.; Tourtellotte, L.M.; Simburger, K.;
Milbrandt, J. Mice deficient in the orphan receptor steroidogenic factor 1 lack adrenal glands and gonads
but express P450 side-chain-cleavage enzyme in the placenta and have normal embryonic serum levels of
corticosteroids. Proc. Natl. Acad. Sci. USA 1995, 92, 10939–10943. [CrossRef]
97. Ferraz-de-Souza, B.; Lin, L.; Achermann, J.C. Steroidogenic factor-1 (SF-1, NR5A1) and human disease. Mol.
Cell. Endocrinol. 2011, 336, 198–205. [CrossRef]
98. Bashamboo, A.; Ferraz-de-Souza, B.; Lourenco, D.; Lin, L.; Sebire, N.J.; Montjean, D.; Bignon-Topalovic, J.;
Mandelbaum, J.; Siffroi, J.P.; Christin-Maitre, S.; et al. Human male infertility associated with mutations in
NR5A1 encoding steroidogenic factor 1. Am. J. Hum. Genet. 2010, 87, 505–512. [CrossRef]
99. Ropke, A.; Tewes, A.C.; Gromoll, J.; Kliesch, S.; Wieacker, P.; Tuttelmann, F. Comprehensive sequence analysis
of the NR5A1 gene encoding steroidogenic factor 1 in a large group of infertile males. Eur. J. Hum. Genet.
2013, 21, 1012–1015. [CrossRef]
100. Ferlin, A.; Rocca, M.S.; Vinanzi, C.; Ghezzi, M.; Di Nisio, A.; Foresta, C. Mutational screening of NR5A1 gene
encoding steroidogenic factor 1 in cryptorchidism and male factor infertility and functional analysis of seven
undescribed mutations. Fertil. Steril. 2015, 104, 163–169.e161. [CrossRef] [PubMed]
101. Zare-Abdollahi, D.; Safari, S.; Mirfakhraie, R.; Movafagh, A.; Bastami, M.; Azimzadeh, P.; Salsabili, N.;
Ebrahimizadeh, W.; Salami, S.; Omrani, M.D. Mutational screening of the NR5A1 in azoospermia. Andrologia
2015, 47, 395–401. [CrossRef] [PubMed]
102. Sudhakar, D.V.S.; Nizamuddin, S.; Manisha, G.; Devi, J.R.; Gupta, N.J.; Chakravarthy, B.N.; Deenadayal, M.;
Singh, L.; Thangaraj, K. NR5A1 mutations are not associated with male infertility in Indian men. Andrologia
2018, 50. [CrossRef] [PubMed]
103. Raymond, C.S.; Shamu, C.E.; Shen, M.M.; Seifert, K.J.; Hirsch, B.; Hodgkin, J.; Zarkower, D. Evidence for
evolutionary conservation of sex-determining genes. Nature 1998, 391, 691–695. [CrossRef] [PubMed]
104. Volff, J.N.; Zarkower, D.; Bardwell, V.J.; Schartl, M. Evolutionary dynamics of the DM domain gene family in
metazoans. J. Mol. Evol. 2003, 57 (Suppl. 1), S241–S249. [CrossRef]
105. Zarkower, D. Establishing sexual dimorphism: Conservation amidst diversity? Nat. Rev. Genet. 2001, 2,
175–185. [CrossRef]
106. Moniot, B.; Berta, P.; Scherer, G.; Sudbeck, P.; Poulat, F. Male specific expression suggests role of DMRT1 in
human sex determination. Mech. Dev. 2000, 91, 323–325. [CrossRef]
107. Huang, S.; Ye, L.; Chen, H. Sex determination and maintenance: The role of DMRT1 and FOXL2. Asian J.
Androl. 2017, 19, 619–624.
108. Raymond, C.S.; Murphy, M.W.; O’Sullivan, M.G.; Bardwell, V.J.; Zarkower, D. Dmrt1, a gene related to worm
and fly sexual regulators, is required for mammalian testis differentiation. Genes Dev. 2000, 14, 2587–2595.
[CrossRef]
109. Lopes, A.M.; Aston, K.I.; Thompson, E.; Carvalho, F.; Goncalves, J.; Huang, N.; Matthiesen, R.; Noordam, M.J.;
Quintela, I.; Ramu, A.; et al. Human spermatogenic failure purges deleterious mutation load from the
autosomes and both sex chromosomes, including the gene DMRT1. PLoS Genet. 2013, 9, e1003349. [CrossRef]
110. Tewes, A.C.; Ledig, S.; Tuttelmann, F.; Kliesch, S.; Wieacker, P. DMRT1 mutations are rarely associated with
male infertility. Fertil. Steril. 2014, 102, 816–820.e813. [CrossRef]
111. Araujo, T.F.; Friedrich, C.; Grangeiro, C.H.P.; Martelli, L.R.; Grzesiuk, J.D.; Emich, J.; Wyrwoll, M.J.; Kliesch, S.;
Simões, A.L.; Tüttelmann, F.; et al. Sequence analysis of 37 candidate genes for male infertility: Challenges
in variant assessment and validating genes. Andrology 2019, in press. [CrossRef] [PubMed]
112. Lima, A.C.; Carvalho, F.; Goncalves, J.; Fernandes, S.; Marques, P.I.; Sousa, M.; Barros, A.; Seixas, S.;
Amorim, A.; Conrad, D.F.; et al. Rare double sex and mab-3-related transcription factor 1 regulatory variants
in severe spermatogenic failure. Andrology 2015, 3, 825–833. [CrossRef] [PubMed]
113. Wang, P.J.; McCarrey, J.R.; Yang, F.; Page, D.C. An abundance of X-linked genes expressed in spermatogonia.
Nat. Genet. 2001, 27, 422–426. [CrossRef] [PubMed]
114. Adelman, C.A.; Petrini, J.H. ZIP4H (TEX11) deficiency in the mouse impairs meiotic double strand break
repair and the regulation of crossing over. PLoS Genet. 2008, 4, e1000042. [CrossRef] [PubMed]
115. Yatsenko, A.N.; Georgiadis, A.P.; Ropke, A.; Berman, A.J.; Jaffe, T.; Olszewska, M.; Westernströer, B.;
Sanfilippo, J.; Kurpisz, M.; Rajkovic, A.; et al. X-linked TEX11 mutations, meiotic arrest, and azoospermia in
infertile men. N. Engl. J. Med. 2015, 372, 2097–2107. [CrossRef]
J. Clin. Med. 2020, 9, 300 22 of 27
116. Yang, F.; Silber, S.; Leu, N.A.; Oates, R.D.; Marszalek, J.D.; Skaletsky, H.; Brown, L.G.; Rozen, S.; Page, D.C.;
Wang, P.J. TEX11 is mutated in infertile men with azoospermia and regulates genome-wide recombination
rates in mouse. EMBOMol. Med. 2015, 7, 1198–1210. [CrossRef]
117. Nakamura, S.; Miyado, M.; Saito, K.; Katsumi, M.; Nakamura, A.; Kobori, Y.; Tanaka, Y.; Ishikawa, H.;
Yoshida, A.; Okada, H.; et al. Next-generation sequencing for patients with non-obstructive azoospermia:
Implications for significant roles of monogenic/oligogenic mutations. Andrology 2017, 5, 824–831. [CrossRef]
118. Ben Khelifa, M.; Ghieh, F.; Boudjenah, R.; Hue, C.; Fauvert, D.; Dard, R.; Garchon, H.J.; Vialard, F.; et al. A
MEI1 homozygous missense mutation associated with meiotic arrest in a consanguineous family. Hum.
Reprod. 2018, 33, 1034–1037. [CrossRef]
119. Sha, Y.; Zheng, L.; Ji, Z.; Mei, L.; Ding, L.; Lin, S.; Wang, X.; Yang, X.; Li, P. A novel TEX11 mutation induces
azoospermia: A case report of infertile brothers and literature review. BMC Med. Genet. 2018, 19, 63.
[CrossRef]
120. Boroujeni, P.B.; Sabbaghian, M.; Totonchi, M.; Sodeifi, N.; Sarkardeh, H.; Samadian, A.; Sadighi-Gilani, M.A.;
Gourabi, H. Expression analysis of genes encoding TEX11, TEX12, TEX14 and TEX15 in testis tissues of men
with non-obstructive azoospermia. JBRA Assist. Reprod. 2018, 22, 185–192. [CrossRef]
121. Greenbaum, M.P.; Yan, W.; Wu, M.H.; Lin, Y.N.; Agno, J.E.; Sharma, M.; Braun, R.E.; Rajkovic, A.; Matzuk, M.M.
TEX14 is essential for intercellular bridges and fertility in male mice. Proc. Natl. Acad. Sci. USA 2006, 103,
4982–4987. [CrossRef] [PubMed]
122. Kim, H.J.; Yoon, J.; Matsuura, A.; Na, J.H.; Lee, W.K.; Kim, H.; Choi, J.W.; Park, J.E.; Park, S.J.; Kim, K.T.; et al.
Structural and biochemical insights into the role of testis-expressed gene 14 (TEX14) in forming the stable
intercellular bridges of germ cells. Proc. Natl. Acad. Sci. USA 2015, 112, 12372–12377. [CrossRef] [PubMed]
123. Fakhro, K.A.; Elbardisi, H.; Arafa, M.; Robay, A.; Rodriguez-Flores, J.L.; Al-Shakaki, A.; Syed, N.; Mezey, J.G.;
Abi Khalil, C.; Malek, J.A.; et al. Point-of-care whole-exome sequencing of idiopathic male infertility. Genet.
Med. 2018, 20, 1365–1373. [CrossRef]
124. Yang, F.; Eckardt, S.; Leu, N.A.; McLaughlin, K.J.; Wang, P.J. Mouse TEX15 is essential for DNA double-strand
break repair and chromosomal synapsis during male meiosis. J. Cell Biol. 2008, 180, 673–679. [CrossRef]
125. Gershoni, M.; Hauser, R.; Yogev, L.; Lehavi, O.; Azem, F.; Yavetz, H.; Pietrokovski, S.; Kleiman, S.E. A familial
study of azoospermic men identifies three novel causative mutations in three new human azoospermia
genes. Genet. Med. 2017, 19, 998–1006. [CrossRef]
126. Okutman, O.; Muller, J.; Baert, Y.; Serdarogullari, M.; Gultomruk, M.; Piton, A.; Rombaut, C.; Benkhalifa, M.;
Teletin, M.; Skory, V.; et al. Exome sequencing reveals a nonsense mutation in TEX15 causing spermatogenic
failure in a Turkish family. Hum. Mol. Genet. 2015, 24, 5581–5588. [CrossRef]
127. Colombo, R.; Pontoglio, A.; Bini, M. Two Novel TEX15 Mutations in a Family with Nonobstructive
Azoospermia. Gynecol. Obstet. Investig. 2017, 82, 283–286. [CrossRef]
128. Zhou, Y.D.; Barnard, M.; Tian, H.; Li, X.; Ring, H.Z.; Francke, U.; Shelton, J.; Richardson, J.; Russell, D.W.;
McKnight, S.L. Molecular characterization of two mammalian bHLH-PAS domain proteins selectively
expressed in the central nervous system. Proc. Natl. Acad. Sci. USA 1997, 94, 713–718. [CrossRef]
129. Reick, M.; Garcia, J.A.; Dudley, C.; McKnight, S.L. NPAS2: An analog of clock operative in the mammalian
forebrain. Science 2001, 293, 506–509. [CrossRef]
130. Ramasamy, R.; Bakircioglu, M.E.; Cengiz, C.; Karaca, E.; Scovell, J.; Jhangiani, S.N.; Akdemir, Z.C.;
Bainbridge, M.; Yu, Y.; Huff, C.; et al. Whole-exome sequencing identifies novel homozygous mutation in
NPAS2 in family with nonobstructive azoospermia. Fertil. Steril. 2015, 104, 286–291. [CrossRef]
131. Choi, Y.; Jeon, S.; Choi, M.; Lee, M.H.; Park, M.; Lee, D.R.; Jun, K.Y.; Kwon, Y.; Lee, O.H.; Song, S.H.; et al.
Mutations in SOHLH1 gene associate with nonobstructive azoospermia. Hum. Mutat. 2010, 31, 788–793.
[CrossRef]
132. Stouffs, K.; Lissens, W.; Tournaye, H.; Van Steirteghem, A.; Liebaers, I. Possible role of USP26 in patients
with severely impaired spermatogenesis. Eur. J. Hum. Genet. 2005, 13, 336–340. [CrossRef]
133. Ma, Q.; Li, Y.; Guo, H.; Li, C.; Chen, J.; Luo, M.; Jiang, Z.; Li, H.; Gui, Y. A Novel Missense Mutation in USP26
Gene Is Associated With Nonobstructive Azoospermia. Reprod. Sci 2016, 23, 1434–1441. [CrossRef]
134. Miyamoto, T.; Hasuike, S.; Yogev, L.; Maduro, M.R.; Ishikawa, M.; Westphal, H.; Lamb, D.J. Azoospermia in
patients heterozygous for a mutation in SYCP3. Lancet 2003, 362, 1714–1719. [CrossRef]
135. Ayhan, O.; Balkan, M.; Guven, A.; Hazan, R.; Atar, M.; Tok, A.; Tolun, A. Truncating mutations in TAF4B and
ZMYND15 causing recessive azoospermia. J. Med. Genet. 2014, 51, 239–244. [CrossRef]
J. Clin. Med. 2020, 9, 300 23 of 27
136. Maor-Sagie, E.; Cinnamon, Y.; Yaacov, B.; Shaag, A.; Goldsmidt, H.; Zenvirt, S.; Laufer, N.; Richler, C.;
Frumkin, A. Deleterious mutation in SYCE1 is associated with non-obstructive azoospermia. J. Assist. Reprod.
Genet. 2015, 32, 887–891. [CrossRef]
137. Tenenbaum-Rakover, Y.; Weinberg-Shukron, A.; Renbaum, P.; Lobel, O.; Eideh, H.; Gulsuner, S.; Dahary, D.;
Abu-Rayyan, A.; Kanaan, M.; Levy-Lahad, E.; et al. Minichromosome maintenance complex component 8
(MCM8) gene mutations result in primary gonadal failure. J. Med. Genet. 2015, 52, 391–399. [CrossRef]
138. Mou, L.; Wang, Y.; Li, H.; Huang, Y.; Jiang, T.; Huang, W.; Li, Z.; Chen, J.; Xie, J.; Liu, Y.; et al. A
dominant-negative mutation of HSF2 associated with idiopathic azoospermia. Hum. Genet. 2013, 132,
159–165. [CrossRef]
139. Kherraf, Z.E.; Christou-Kent, M.; Karaouzene, T.; Amiri-Yekta, A.; Martinez, G.; Vargas, A.S.; Lambert, E.;
Borel, C.; Dorphin, B.; Aknin-Seifer, I.; et al. SPINK2 deficiency causes infertility by inducing sperm defects
in heterozygotes and azoospermia in homozygotes. EMBOMol. Med. 2017, 9, 1132–1149. [CrossRef]
140. Arafat, M.; Har-Vardi, I.; Harlev, A.; Levitas, E.; Zeadna, A.; Abofoul-Azab, M.; Dyomin, V.; Sheffield, V.C.;
Lunenfeld, E.; Huleihel, M.; et al. Mutation in TDRD9 causes non-obstructive azoospermia in infertile men.
J. Med. Genet. 2017, 54, 633–639. [CrossRef]
141. Krausz, C. Male infertility: Pathogenesis and clinical diagnosis. Best Pract. Res. Clin. Endocrinol. Metab. 2011,
25, 271–285. [CrossRef] [PubMed]
142. Tuttelmann, F.; Rajpert-De Meyts, E.; Nieschlag, E.; Simoni, M. Gene polymorphisms and male infertility–a
meta-analysis and literature review. Reprod. Biomed. Online 2007, 15, 643–658. [CrossRef]
143. Mobasseri, N.; Babaei, F.; Karimian, M.; Nikzad, H. Androgen receptor (AR)-CAG trinucleotide repeat
length and idiopathic male infertility: A case-control trial and a meta-analysis. EXCLI J. 2018, 17, 1167–1179.
[PubMed]
144. Pan, B.; Li, R.; Chen, Y.; Tang, Q.; Wu, W.; Chen, L.; Lu, C.; Pan, F.; Ding, H.; Xia, Y.; et al. Genetic Association
between Androgen Receptor Gene CAG Repeat Length Polymorphism and Male Infertility: A Meta-Analysis.
Medicine 2016, 95, e2878. [CrossRef]
145. Munoz, X.; Navarro, M.; Mata, A.; Bassas, L.; Larriba, S. Association of PIWIL4 genetic variants with germ
cell maturation arrest in infertile Spanish men. Asian J. Androl. 2014, 16, 931–933.
146. Kamaliyan, Z.; Pouriamanesh, S.; Amin-Beidokhti, M.; Rezagholizadeh, A.; Mirfakhraie, R. HIWI2 rs508485
Polymorphism is Associated with Non-obstructive Azoospermia in Iranian Patients. Rep. Biochem. Mol. Biol.
2017, 5, 108–111.
147. Kamaliyan, Z.; Pouriamanesh, S.; Soosanabadi, M.; Gholami, M.; Mirfakhraie, R. Investigation of
piwi-interacting RNA pathway genes role in idiopathic non-obstructive azoospermia. Sci. Rep. 2018,
8, 142. [CrossRef]
148. Stuppia, L.; Gatta, V.; Scarciolla, O.; Colosimo, A.; Guanciali-Franchi, P.; Calabrese, G.; Palka, G. The
methylenetethrahydrofolate reductase (MTHFR) C677T polymorphism and male infertility in Italy. J.
Endocrinol. Investig. 2003, 26, 620–622. [CrossRef]
149. Gava, M.M.; Kayaki, E.A.; Bianco, B.; Teles, J.S.; Christofolini, D.M.; Pompeo, A.C.; Glina, S.; Barbosa, C.P.
Polymorphisms in folate-related enzyme genes in idiopathic infertile Brazilian men. Reprod. Sci. 2011, 18,
1267–1272. [CrossRef]
150. Kim, S.Y.; Lim, J.W.; Kim, J.W.; Park, S.Y.; Seo, J.T. Association between genetic polymorphisms in folate-related
enzyme genes and infertile men with non-obstructive azoospermia. Syst. Biol. Reprod. Med. 2015, 61,
286–292.
151. Lee, H.C.; Jeong, Y.M.; Lee, S.H.; Cha, K.Y.; Song, S.H.; Kim, N.K.; Lee, K.W.; Lee, S. Association study of
four polymorphisms in three folate-related enzyme genes with non-obstructive male infertility. Hum. Reprod.
2006, 21, 3162–3170. [CrossRef] [PubMed]
152. Ying, H.Q.; Pu, X.Y.; Liu, S.R.; A, Z.-C. Genetic variants of eNOS gene may modify the susceptibility to
idiopathic male infertility. Biomarkers 2013, 18, 412–417. [CrossRef] [PubMed]
153. Chang, J.; Pan, F.; Tang, Q.; Wu, W.; Chen, M.; Lu, C.; Ding, H.; Hu, L.; Chen, D.; Xia, Y.; et al. eNOS gene
T786C, G894T and 4a4b polymorphisms and male infertility susceptibility: A meta-analysis. Andrologia 2017,
49. [CrossRef]
154. Ying, H.Q.; Scott, M.B.; Zhou-Cun, A. Relationship of SNP of H2BFWT gene to male infertility in a Chinese
population with idiopathic spermatogenesis impairment. Biomarkers 2012, 17, 402–406. [CrossRef]
J. Clin. Med. 2020, 9, 300 24 of 27
155. Rafatmanesh, A.; Nikzad, H.; Ebrahimi, A.; Karimian, M.; Zamani, T. Association of the c.-9C>T and
c.368A>G transitions in H2BFWT gene with male infertility in an Iranian population. Andrologia 2018, 50.
[CrossRef]
156. Haji Ebrahim Zargar, H.; Mohseni Meybodi, A.; Sabbaghian, M.; Shahhoseini, M.; Asadpor, U.; Sadighi
Gilani, M.A.; Chehrazi, M.; Farhangniya, M.; Shahzadeh Fazeli, S.A. Association of Two Polymorphisms in
H2B.W Gene with Azoospermia and Severe Oligozoospermia in An Iranian Population. Int. J. Fertil. Steril.
2015, 9, 205–214.
157. Yoshida, K.I.; Yano, M.; Chiba, K.; Honda, M.; Kitahara, S. CAG repeat length in the androgen receptor gene
is enhanced in patients with idiopathic azoospermia. Urology 1999, 54, 1078–1081. [CrossRef]
158. Sato, H.; Miyamoto, T.; Yogev, L.; Namiki, M.; Koh, E.; Hayashi, H.; Sasaki, Y.; Ishikawa, M.; Lamb, D.J.;
Matsumoto, N.; et al. Polymorphic alleles of the human MEI1 gene are associated with human azoospermia
by meiotic arrest. J. Hum. Genet. 2006, 51, 533–540. [CrossRef]
159. Wilson, G.R.; Sim, M.L.; Brody, K.M.; Taylor, J.M.; McLachlan, R.I.; O’Bryan, M.K.; Delatycki, M.B.;
Lockhart, P.J. Molecular analysis of the PArkin co-regulated gene and association with male infertility. Fertil.
Steril. 2010, 93, 2262–2268. [CrossRef]
160. Ma, J.; Lu, H.Y.; Xia, Y.K.; Dong, H.B.; Gu, A.H.; Li, Z.Y.; Li, Z.; Chen, A.M.; Wang, X.R.; Wang, S.L. BCL2
Ala43Thr is a functional variant associated with protection against azoospermia in a Han-Chinese population.
Biol. Reprod. 2010, 83, 656–662. [CrossRef]
161. Aston, K.I.; Krausz, C.; Laface, I.; Ruiz-Castane, E.; Carrell, D.T. Evaluation of 172 candidate polymorphisms
for association with oligozoospermia or azoospermia in a large cohort of men of European descent. Hum.
Reprod. 2010, 25, 1383–1397. [CrossRef]
162. Hu, Z.; Xia, Y.; Guo, X.; Dai, J.; Li, H.; Hu, H.; Jiang, Y.; Lu, F.; Wu, Y.; Yang, X.; et al. A genome-wide
association study in Chinese men identifies three risk loci for non-obstructive azoospermia. Nat. Genet. 2011,
44, 183–186. [CrossRef] [PubMed]
163. Zhao, H.; Xu, J.; Zhang, H.; Sun, J.; Sun, Y.; Wang, Z.; Liu, J.; Ding, Q.; Lu, S.; Shi, R.; et al. A genome-wide
association study reveals that variants within the HLA region are associated with risk for nonobstructive
azoospermia. Am. J. Hum. Genet. 2012, 90, 900–906. [CrossRef] [PubMed]
164. Li, Z.; Yu, J.; Zhang, T.; Li, H.; Ni, Y. rs189037, a functional variant in ATM gene promoter, is associated with
idiopathic nonobstructive azoospermia. Fertil. Steril. 2013, 100, 1536–1541.e1531. [CrossRef] [PubMed]
165. Hu, Z.; Li, Z.; Yu, J.; Tong, C.; Lin, Y.; Guo, X.; Lu, F.; Dong, J.; Xia, Y.; Wen, Y.; et al. Association analysis
identifies new risk loci for non-obstructive azoospermia in Chinese men. Nat. Commun. 2014, 5, 3857.
[CrossRef]
166. Qin, Y.; Ji, J.; Du, G.; Wu, W.; Dai, J.; Hu, Z.; Sha, J.; Hang, B.; Lu, C.; Xia, Y.; et al. Comprehensive
pathway-based analysis identifies associations of BCL2, GNAO1 and CHD2 with non-obstructive azoospermia
risk. Hum. Reprod. 2014, 29, 860–866. [CrossRef]
167. Ni, B.; Ma, H.; Lin, Y.; Dai, J.; Guo, X.; Xia, Y.; Sha, J.; Hu, Z. Genetic variants in Ser-Arg protein-coding genes
are associated with the risk of nonobstructive azoospermia in Chinese men. Fertil. Steril. 2014, 101, 1711-7
e1–1711-7 e2. [CrossRef]
168. Ghalkhani, E.; Sheidai, M.; Gourabi, H.; Noormohammadi, Z.; Bakhtari, N.; Malekasgar, A.M. Study of single
nucleotide polymorphism (rs28368082) in SPO11 gene and its association with male infertility. J. Assist.
Reprod. Genet. 2014, 31, 1205–1210. [CrossRef]
169. Xiong, D.K.; Chen, H.H.; Ding, X.P.; Zhang, S.H.; Zhang, J.H. Association of polymorphisms in glutathione
S-transferase genes (GSTM1, GSTT1, GSTP1) with idiopathic azoospermia or oligospermia in Sichuan, China.
Asian J. Androl. 2015, 17, 481–486. [CrossRef]
170. Zhang, Y.; He, X.J.; Song, B.; Ye, L.; Xie, X.S.; Ruan, J.; Zhou, F.S.; Zuo, X.B.; Cao, Y.X.; Du, W.D. Association
of single nucleotide polymorphisms in the USF1, GTF2A1L and OR2W3 genes with non-obstructive
azoospermia in the Chinese population. J. Assist. Reprod. Genet. 2015, 32, 95–101. [CrossRef]
171. Sato, Y.; Tajima, A.; Tsunematsu, K.; Nozawa, S.; Yoshiike, M.; Koh, E.; Kanaya, J.; Namiki, M.; Matsumiya, K.;
Tsujimura, A.; et al. An association study of four candidate loci for human male fertility traits with male
infertility. Hum. Reprod. 2015, 30, 1510–1514. [CrossRef] [PubMed]
172. Gharesi-Fard, B.; Ghasemi, Z.; Shakeri, S.; Behdin, S.; Aghaei, F.; Malek-Hosseini, Z. The frequency of follicle
stimulating hormone receptor gene polymorphisms in Iranian infertile men with azoospermia. Iran. J.
Reprod. Med. 2015, 13, 673–678. [PubMed]
J. Clin. Med. 2020, 9, 300 25 of 27
173. Zhang, X.; Ding, M.; Ding, X.; Li, T.; Chen, H. Six polymorphisms in genes involved in DNA double-strand
break repair and chromosome synapsis: Association with male infertility. Syst. Biol. Reprod. Med. 2015, 61,
187–193. [CrossRef] [PubMed]
174. Zhang, W.; Lin, W.Q.; Cao, H.F.; Li, C.Y.; Li, F. Association of a miR-34b binding site single nucleotide
polymorphism in the 3’-untranslated region of the methylenetetrahydrofolate reductase gene with
susceptibility to male infertility. Genet. Mol. Res. 2015, 14, 12196–12204. [CrossRef] [PubMed]
175. Song, B.; Zhang, Y.; He, X.J.; Du, W.D.; Ruan, J.; Zhou, F.S.; Wu, H.; Zha, X.; Xie, X.S.; Ye, L.; et al. Association of
genetic variants in SOHLH1 and SOHLH2 with non-obstructive azoospermia risk in the Chinese population.
Eur. J. Obstet. Gynecol. Reprod. Biol. 2015, 184, 48–52. [CrossRef]
176. Lu, J.; Gu, H.; Tang, Q.; Wu, W.; Yuan, B.; Guo, D.; Wei, Y.; Sun, H.; Xia, Y.; Ding, H.; et al. Common SNP
in hsa-miR-196a-2 increases hsa-miR-196a-5p expression and predisposes to idiopathic male infertility in
Chinese Han population. Sci. Rep. 2016, 6, 19825. [CrossRef]
177. Chihara, M.; Yoshihara, K.; Ishiguro, T.; Adachi, S.; Okada, H.; Kashima, K.; Sato, T.; Tanaka, A.; Tanaka, K.;
Enomoto, T. Association of NR3C1/Glucocorticoid Receptor gene SNP with azoospermia in Japanese men. J.
Obstet. Gynaecol. Res. 2016, 42, 59–66. [CrossRef]
178. Zhu, X.; Liu, Z.; Zhang, M.; Gong, R.; Xu, Y.; Wang, B. Association of the methylenetetrahydrofolate reductase
gene C677T polymorphism with the risk of male infertility: A meta-analysis. Ren. Fail. 2016, 38, 185–193.
[CrossRef]
179. Najafipour, R.; Rashvand, Z.; Alizadeh, A.; Aleyasin, A.; Moghbelinejad, S. Association of G/T(rs222859)
polymorphism in Exon 1 of YBX2 gene with azoospermia, among Iranian infertile males. Andrologia 2016, 48,
956–960. [CrossRef]
180. Ramgir, S.S.; Sekar, N.; Jindam, D.; Abilash, V.G. Association of CYP1A1*2A Polymorphism with Idiopathic
Non-Obstructive Azoospermia in A South Indian Cohort. Int. J. Fertil. Steril. 2017, 11, 142–147.
181. Asgari, R.; Mansouri, K.; Bakhtiari, M.; Bidmeshkipour, A.; Yari, K.; Shaveisi-Zadeh, F.; Vaisi-Raygani, A.
Association of FAS-670A/G and FASL-844C/T polymorphisms with idiopathic azoospermia in Western Iran.
Eur. J. Obstet. Gynecol. Reprod. Biol. 2017, 218, 55–59. [CrossRef] [PubMed]
182. Jahantigh, D.; Hosseinzadeh Colagar, A. XRCC5 VNTR, XRCC6 -61C>G, and XRCC7 6721G>T Gene
Polymorphisms Associated with Male Infertility Risk: Evidences from Case-Control and In Silico Studies.
Int. J. Endocrinol. 2017, 2017, 4795076. [CrossRef] [PubMed]
183. Ashrafzadeh, H.R.; Nazari, T.; Dehghan Tezerjani, M.; Khademi Bami, M.; Ghasemi-Esmailabad, S.;
Ghasemi, N. Frequency of TNFR1 36 A/G gene polymorphism in azoospermic infertile men: A case-control
study. Int. J. Reprod. Biomed. 2017, 15, 521–526. [CrossRef]
184. Moghbelinejad, S.; Najafipour, R.; Momeni, A. Association of rs1057035polymorphism in microRNA
biogenesis pathway gene (DICER1) with azoospermia among Iranian population. Genes Genom. 2018, 40,
17–24. [CrossRef]
185. Sato, Y.; Hasegawa, C.; Tajima, A.; Nozawa, S.; Yoshiike, M.; Koh, E.; Kanaya, J.; Namiki, M.; Matsumiya, K.;
Tsujimura, A.; et al. Association of TUSC1 and DPF3 gene polymorphisms with male infertility. J. Assist.
Reprod. Genet. 2018, 35, 257–263. [CrossRef]
186. Teimouri, M.; Najaran, H.; Hosseinzadeh, A.; Mazoochi, T. Association between two common transitions of
H2BFWT gene and male infertility: A case-control, meta, and structural analysis. Andrology 2018, 6, 306–316.
[CrossRef]
187. Zamani-Badi, T.; Karimian, M.; Azami Tameh, A.; Nikzad, H. IL-1a C376A Transversion Variant and Risk of
Idiopathic Male Infertility in Iranian Men: A Genetic Association Study. Int. J. Fertil. Steril. 2018, 12, 229–234.
188. Zamani-Badi, T.; Nikzad, H.; Karimian, M. IL-1RA VNTR and IL-1alpha 4845G>T polymorphisms and risk
of idiopathic male infertility in Iranian men: A case-control study and an in silico analysis. Andrologia 2018,
50, e13081. [CrossRef]
189. Yu, C.H.; Xie, T.; Zhang, R.P.; A, Z.-C. Association of the common SNPs in RNF212, STAG3 and RFX2 gene
with male infertility with azoospermia in Chinese population. Eur. J. Obstet. Gynecol. Reprod. Biol. 2018, 221,
109–112. [CrossRef]
190. Singh, V.; Bansal, S.K.; Sudhakar, D.V.S.; Neelabh Chakraborty, A.; Trivedi, S.; et al. SNPs in ERCC1,
ERCC2, and XRCC1 genes of the DNA repair pathway and risk of male infertility in the Asian populations:
Association study, meta-analysis, and trial sequential analysis. J. Assist. Reprod. Genet. 2019, 36, 79–90.
[CrossRef]
J. Clin. Med. 2020, 9, 300 26 of 27
191. Busch, A.S.; Tuttelmann, F.; Cremers, J.F.; Schubert, M.; Nordhoff, V.; Schuring, A.N.; Zitzmann, M.;
Gromoll, J.; Kliesch, S. FSHB -211 G>T Polymorphism as Predictor for TESE Success in Patients with
Unexplained Azoospermia. J. Clin. Endocrinol. Metab. 2019, 104, 2315–2324. [CrossRef] [PubMed]
192. Zhao, X.; Mu, C.; Ma, J.; Dai, X.; Jiao, H. The association of four SNPs in DNA mismatch repair genes with
idiopathic male infertility in northwest China. Int. J. Immunogenet. 2019, 46, 451–458. [CrossRef]
193. Huang, M.; Zhu, M.; Jiang, T.; Wang, Y.; Wang, C.; Jin, G.; Guo, X.; Sha, J.; Dai, J.; Wang, X.; et al. Fine
mapping the MHC region identified rs4997052 as a new variant associated with nonobstructive azoospermia
in Han Chinese males. Fertil. Steril. 2019, 111, 61–68. [CrossRef] [PubMed]
194. Nam, Y.; Kang, K.M.; Sung, S.R.; Park, J.E.; Shin, Y.J.; Song, S.H.; Seo, J.T.; Yoon, T.K.; Shim, S.H. The
association of stromal antigen 3 (STAG3) sequence variations with spermatogenic impairment in the male
Korean population. Asian J. Androl. 2020, 22, 106–111. [PubMed]
195. Pennisi, E. Breakthrough of the year. Human genetic variation. Science 2007, 318, 1842–1843. [CrossRef]
196. Hofker, M.H.; Fu, J.; Wijmenga, C. The genome revolution and its role in understanding complex diseases.
Biochim. Biophys. Acta 2014, 1842, 1889–1895. [CrossRef]
197. Aston, K.I.; Carrell, D.T. Genome-wide study of single-nucleotide polymorphisms associated with
azoospermia and severe oligozoospermia. J. Androl. 2009, 30, 711–725. [CrossRef]
198. Johnson, R.C.; Nelson, G.W.; Troyer, J.L.; Lautenberger, J.A.; Kessing, B.D.; Winkler, C.A.; et al. Accounting
for multiple comparisons in a genome-wide association study (GWAS). BMCGenom. 2010, 11, 724. [CrossRef]
199. Pe’er, I.; Yelensky, R.; Altshuler, D.; Daly, M.J. Estimation of the multiple testing burden for genomewide
association studies of nearly all common variants. Genet. Epidemiol. 2008, 32, 381–385. [CrossRef]
200. Fadista, J.; Manning, A.K.; Florez, J.C.; Groop, L. The (in)famous GWAS P-value threshold revisited and
updated for low-frequency variants. Eur. J. Hum. Genet. 2016, 24, 1202–1205. [CrossRef]
201. Xu, M.; Qin, Y.; Qu, J.; Lu, C.; Wang, Y.; Wu, W.; Song, L.; Wang, S.; Chen, F.; Shen, H.; et al. Evaluation of
five candidate genes from GWAS for association with oligozoospermia in a Han Chinese population. PLoS
ONE 2013, 8, e80374. [CrossRef] [PubMed]
202. Sato, Y.; Jinam, T.; Iwamoto, T.; Yamauchi, A.; Imoto, I.; Inoue, I.; Tajima, A. Replication study and
meta-analysis of human nonobstructive azoospermia in Japanese populations. Biol. Reprod. 2013, 88, 87.
[CrossRef] [PubMed]
203. Gu, X.; Li, H.; Chen, X.; Zhang, X.; Mei, F.; Jia, M.; Xiong, C. PEX10, SIRPA-SIRPG, and SOX5 gene
polymorphisms are strongly associated with nonobstructive azoospermia susceptibility. J. Assist. Reprod.
Genet. 2019, 36, 759–768. [CrossRef]
204. Zhang, Y.; Qian, J.; Wu, M.; Liu, M.; Zhang, K.; Lin, Y.; Guo, X.; Zhou, Z.; Hu, Z.; Sha, J. A susceptibility locus
rs7099208 is associated with non-obstructive azoospermia via reduction in the expression of FAM160B1. J.
Biomed. Res. 2015, 29, 491–500.
205. Zou, S.; Song, P.; Meng, H.; Chen, T.; Chen, J.; Wen, Z.; Li, Z.; Shi, Y.; Hu, H. Association and meta-analysis of
HLA and non-obstructive azoospermia in the Han Chinese population. Andrologia 2017, 49. [CrossRef]
206. Perez, C.V.; Theas, M.S.; Jacobo, P.V.; Jarazo-Dietrich, S.; Guazzone, V.A.; Lustig, L. Dual role of immune cells
in the testis: Protective or pathogenic for germ cells? Spermatogenesis 2013, 3, e23870. [CrossRef]
207. Jinam, T.A.; Nakaoka, H.; Hosomichi, K.; Mitsunaga, S.; Okada, H.; Tanaka, A.; Tanaka, K.; Inoue, I.
HLA-DPB1*04:01 allele is associated with non-obstructive azoospermia in Japanese patients. Hum. Genet.
2013, 132, 1405–1411. [CrossRef]
208. Kosova, G.; Scott, N.M.; Niederberger, C.; Prins, G.S.; Ober, C. Genome-wide association study identifies
candidate genes for male fertility traits in humans. Am. J. Hum. Genet. 2012, 90, 950–961. [CrossRef]
209. Ni, B.; Lin, Y.; Sun, L.; Zhu, M.; Li, Z.; Wang, H.; Yu, J.; Guo, X.; Zuo, X.; Dong, J.; et al. Low-frequency
germline variants across 6p22.2-6p21.33 are associated with non-obstructive azoospermia in Han Chinese
men. Hum. Mol. Genet. 2015, 24, 5628–5636.
210. Tuttelmann, F.; Simoni, M.; Kliesch, S.; Ledig, S.; Dworniczak, B.; Wieacker, P.; Ropke, A. Copy number
variants in patients with severe oligozoospermia and Sertoli-cell-only syndrome. PLoS ONE 2011, 6, e19426.
[CrossRef]
211. Krausz, C.; Giachini, C.; Lo Giacco, D.; Daguin, F.; Chianese, C.; Ars, E.; Ruiz-Castane, E.; Forti, G.; Rossi, E.
High resolution X chromosome-specific array-CGH detects new CNVs in infertile males. PLoS ONE 2012, 7,
e44887. [CrossRef]
J. Clin. Med. 2020, 9, 300 27 of 27
212. Stouffs, K.; Vandermaelen, D.; Massart, A.; Menten, B.; Vergult, S.; Tournaye, H.; Lissens, W. Array
comparative genomic hybridization in male infertility. Hum. Reprod. 2012, 27, 921–929. [CrossRef] [PubMed]
213. Lo Giacco, D.; Chianese, C.; Ars, E.; Ruiz-Castane, E.; Forti, G.; Krausz, C. Recurrent X chromosome-linked
deletions: Discovery of new genetic factors in male infertility. J. Med. Genet. 2014, 51, 340–344. [CrossRef]
[PubMed]
214. Wu, W.; Qin, Y.; Li, Z.; Dong, J.; Dai, J.; Lu, C.; Guo, X.; Zhao, Y.; Zhu, Y.; Zhang, W.; et al. Genome-wide
microRNA expression profiling in idiopathic non-obstructive azoospermia: Significant up-regulation of
miR-141, miR-429 and miR-7-1-3p. Hum. Reprod. 2013, 28, 1827–1836. [CrossRef] [PubMed]
215. Jiang, T.; Wang, Y.; Zhu, M.; Huang, M.; Jin, G.; Guo, X.; Sha, J.; Dai, J.; Hu, Z. Transcriptome-wide association
study revealed two novel genes associated with nonobstructive azoospermia in a Chinese population. Fertil.
Steril. 2017, 108, 1056–1062.e1054. [CrossRef] [PubMed]
216. Ferfouri, F.; Boitrelle, F.; Ghout, I.; Albert, M.; Molina Gomes, D.; Wainer, R.; Bailly, M.; Selva, J.; Vialard, F. A
genome-wide DNA methylation study in azoospermia. Andrology 2013, 1, 815–821. [CrossRef] [PubMed]
217. Han, F.; Jiang, X.; Li, Z.M.; Zhuang, X.; Zhang, X.; Ouyang, W.M.; Liu, W.B.; Mao, C.Y.; Chen, Q.; Huang, C.S.;
et al. Epigenetic Inactivation of SOX30 Is Associated with Male Infertility and Offers a Therapy Target for
Non-obstructive Azoospermia. Mol. Ther. Nucleic Acids 2019, 19, 72–83. [CrossRef]
218. Cannarella, R.; Condorelli, R.A.; Duca, Y.; La Vignera, S.; Calogero, A.E. New insights into the genetics of
spermatogenic failure: A review of the literature. Hum. Genet. 2019, 138, 125–140. [CrossRef]
219. Chalmel, F.; Lardenois, A.; Evrard, B.; Mathieu, R.; Feig, C.; Demougin, P.; Gattiker, A.; Schulze, W.; Jegou, B.;
Kirchhoff, C.; et al. Global human tissue profiling and protein network analysis reveals distinct levels of
transcriptional germline-specificity and identifies target genes for male infertility. Hum. Reprod. 2012, 27,
3233–3248. [CrossRef]
220. Yan, W. Male infertility caused by spermiogenic defects: Lessons from gene knockouts. Mol. Cell. Endocrinol.
2009, 306, 24–32. [CrossRef]
221. Guo, J.; Grow, E.J.; Mlcochova, H.; Maher, G.J.; Lindskog, C.; Nie, X.; Guo, Y.; Takei, Y.; Yun, J.; Cai, L.; et al.
The adult human testis transcriptional cell atlas. Cell Res. 2018, 28, 1141–1157. [CrossRef]
222. Mitchell, M.J.; Metzler-Guillemain, C.; Toure, A.; Coutton, C.; Arnoult, C.; Ray, P.F. Single gene defects
leading to sperm quantitative anomalies. Clin. Genet. 2017, 91, 208–216. [CrossRef]
223. Ghieh, F.; Mitchell, V.; Mandon-Pepin, B.; Vialard, F. Genetic defects in human azoospermia. Basic Clin.
Androl. 2019, 29, 4. [CrossRef] [PubMed]
224. Asero, P.; Calogero, A.E.; Condorelli, R.A.; Mongioi, L.; Vicari, E.; Lanzafame, F.; et al. Relevance of genetic
investigation in male infertility. J. Endocrinol. Investig. 2014, 37, 415–427. [CrossRef] [PubMed]
225. Punab, M.; Poolamets, O.; Paju, P.; Vihljajev, V.; Pomm, K.; Ladva, R.; et al. Causes of male infertility: A
9-year prospective monocentre study on 1737 patients with reduced total sperm counts. Hum. Reprod. 2017,
32, 18–31. [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
